output
listlengths 0
91
| instruction
stringlengths 230
1.72k
| input
stringclasses 1
value |
|---|---|---|
[
{
"end_pos": 19,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 34,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 43,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 59,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 84,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 112,
"label_type": "药物",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 115,
"label_type": "药物",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 156,
"label_type": "手术",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 179,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 188,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 194
},
{
"end_pos": 224,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 220
},
{
"end_pos": 239,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 306,
"label_type": "药物",
"overlap": 0,
"start_pos": 303
},
{
"end_pos": 316,
"label_type": "药物",
"overlap": 0,
"start_pos": 314
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于约4月前无明显诱因上开始出现阴道出血，于******健院行宫颈活检提示中分化鳞癌，后至我院行病理会诊提示低分化癌，考虑为低分化鳞状细胞癌。临床考虑宫颈癌IIA2期。2016-01-18、2016-2-15于我院行力朴素+顺铂方案2程。2016-03-15全麻上行III型子宫切除、两附件切除、盆腔淋巴结清扫。术后病理：（子宫）镜检为宫颈低分化鳞状细胞癌，浸润宫颈及宫颈管深肌层；累及阴道穹窿；可见脉管内癌栓，未见明确神经束侵犯；萎缩性子宫内膜；平滑肌瘤。送检（左髂内淋巴结）1枚，见癌转移，其余多组淋巴结送检均未见癌。术后恢复好，现患者按主诊教授意见入院行术后辅助化疗，2016-04-07给予TC（力扑素240MGD1+顺铂50MGD1）方案化疗1程顺利，无不适。查体无特殊。患者发病以来,精神、饮食、睡眠尚可,大小便无明显异常。体重无明显减轻。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 32,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 37,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 152,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 183,
"label_type": "手术",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 212,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 202
},
{
"end_pos": 323,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 275
},
{
"end_pos": 341,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 329
},
{
"end_pos": 442,
"label_type": "药物",
"overlap": 0,
"start_pos": 439
},
{
"end_pos": 483,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 479
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2个月前因下腹部不适于我院就诊，，入院后行胃镜检查示：于胃体上部、胃角后壁处可见较深凹陷性病变，占胃腔1/2周，中央可见巨大溃疡，表面覆污苔，周围粘膜不规则，有明显浸润并周边呈堤形隆起；病变部位胃腔狭小，内镜尚能通过；贲门部未受侵犯。胃镜病理（201600649），示：（胃角、胃体后壁）低分化腺癌。于2016-01-14在全麻上行根治性胃癌根治术+毕I式吻合，，术后病理示：（201600925）胃体、胃窦低分化腺癌，浸润溃疡型，体积14*9*1.6CM，侵穿浆膜，并于部分脉管内查见癌栓。累及近端切线，远端切线及另送“远端切线”未查见癌。呈三组（3/3个）、四组（11/17个）、六组（9/11个）、“胃1、3、7组”（2/5个）淋巴结癌转移。 “胃第六组”（1个）淋巴结未查见癌。，癌组织免疫组化染色示：RRM1（-）、TS局灶（+）、TOPOII部分（+）、 β-TUBULIN-III（-）、SYN（-）、CERBB-2（-）。术后给予静脉营养、抑酸、补液、补充白蛋白、抗感染等对症治疗。患者恢复良好出院，现患者为进一步行化疗来我院，门诊以“胃癌术后”收入我科。 患者自发病以来，精神可，饮食欠佳，睡眠可，二便正常，体重体力无明显改变。 | |
[
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 65,
"label_type": "手术",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 118,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 136,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 157
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 253,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 256,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 263,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 262
},
{
"end_pos": 266,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 290,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 283
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。入院前3月，患者因结肠镜发现左半结肠肿瘤就诊于我院我科，于2015-09-23我院在全麻上行“剖腹探查、结肠癌根治术、肠粘连松解术”，手术顺利，术后予止血、预防性抗感染、补液、对症等治疗。术后病检（1508028）：（升结肠）粘液性腺癌，侵及全层，远、近切缘未见癌累及，肠周脂肪组织中淋巴结未见癌转移（0/8），（肠系膜结节）见癌组织（2枚），（腹膜结节）未见癌组织。术后恢复可，病情好转出院。于2015-10-20及2015-11-10在我科行化疗，目前患者无畏寒、发热，无咳嗽、咳痰，无恶心、呕吐，无腹痛、腹泻，无胸闷、胸痛、心悸等不适。患者为求第三次化疗，以“左半结肠癌术后3月，拟行第四次化疗”收入我科住院治疗。 | |
[
{
"end_pos": 34,
"label_type": "手术",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 94,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 126,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 114
},
{
"end_pos": 130,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 161,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 248,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 247
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者7月前于我院行剖腹探查+胃癌根治（D2，R1）+放射性粒子植入术，手术顺利，术后安返病房，术后给予补液、消肿、营养支持等对症处理，术后患者恢复顺利，术后病理检查结果：（胃窦）低分化腺癌。胃第八组淋巴结）可见癌转移（1/1）。（胃窦）溃疡型低分化腺癌，浸及胃壁全层，神经见癌侵犯，脉管中见癌栓，上切端见癌累及，下切端食管复鳞下皮轻度不典型增生，胃小弯、大弯淋巴结见癌转移（各为7/8、7/8），网膜中未见癌转移，患者出院后无特处不适。1周前无明显诱因出现全身乏力，且食欲减退，无畏寒、发热，无腹痛，无恶心呕吐等症状，为弄清病情并及时治疗，今入我院我科。\U0004 患者自起病以来，精神略差，胃纳较差，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 21,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 39,
"label_type": "手术",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 70,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 117,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 146,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 192,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 221,
"label_type": "药物",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 224,
"label_type": "药物",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 228,
"label_type": "药物",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 268,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 263
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者6月余前（2015-7-16）因结肠癌于我院行左半结肠切除术+淋巴结清扫术，术后常规病理示：（25232.15）（左半结肠）中低分化腺癌，溃疡型，切面积6*4.5CM，侵达外膜，下上切缘、阑尾及另送吻合器切缘均未查见癌。肠周淋巴结14枚，其中7枚查见转移（7/14）；另送肠系膜根部淋巴结1枚，未查见转移癌（0/1）。术后给予消炎营养支持治疗，病情好转后出院。后患者因“术后肠梗阻”再次入院，行保守治疗好转后出院。后患者再次返院行奥沙利铂+CF+替加氟方案化疗5周期，耐受好。现患者为行上一周期化疗治疗再次来我院，门诊以“结肠癌术后化疗”收入院。自发病来，患者饮食睡眠尚可，二便无明显异常，体重较前无明显改变。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 53,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 76,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 90,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 146,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 145
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 445,
"label_type": "药物",
"overlap": 0,
"start_pos": 441
},
{
"end_pos": 458,
"label_type": "药物",
"overlap": 0,
"start_pos": 453
},
{
"end_pos": 482,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 481
},
{
"end_pos": 485,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 484
},
{
"end_pos": 507,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 506
},
{
"end_pos": 510,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 509
},
{
"end_pos": 552,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 547
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余于我院诊断为直肠癌，于2016-01-21在全麻上行腹腔镜上直肠癌姑息性切除术DIXON，，术后病理：（201602459）1、（直肠），：肠溃疡型管状腺癌II级，侵及外膜层。手术标本下、上切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结0/6个，未见癌转移。肠周脂肪组织中找到12枚癌结节。2、（肠系膜上动脉根部淋巴结），：送检为纤维、脂肪及脉管组织。3、（盆壁结节），：送检为癌结节。，免疫组化：KI67（50%+），CK7（-），CK20（+++），VILLIN（++++），CDX-2（+++），CD56（-），MLH1（+），MSH2（+），PMS2（-），MSH-6（+）。，微卫星稳定性：MSI-L。，病理：（MM20160170）该病例检测到KRAS基因12号密码子G12D突变。，病理：(MM20160171)该病例未检测到BRAF基因V600E突变。术后给予对症、营养支持等治疗，恢复可。于2016.03.19,2016.5.4予“伊立替康240MGD1+卡培他滨片1500MGBIDD1-14”方案化疗，辅以保胃、保肝、增强免疫等，未见明显化疗副反应。出院后无腹痛、腹胀，无呕血、黑便，无发热、寒战等。此次为行上一周期化疗再次就诊我院，门诊拟直肠癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 61,
"label_type": "手术",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 73,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 100,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 144
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 156
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 180
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 208,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 206
},
{
"end_pos": 279,
"label_type": "药物",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 298,
"label_type": "药物",
"overlap": 0,
"start_pos": 294
},
{
"end_pos": 340,
"label_type": "手术",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 365,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 363
},
{
"end_pos": 371,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 366
},
{
"end_pos": 393,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 392
},
{
"end_pos": 396,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 395
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前4月余于我院诊为“胃癌、直肠癌”，于2016.6.11在全麻上行“全腹腔镜上根治性远端胃大部切除术+直肠癌根治术”。术后病理示“（远端胃)胃角溃疡型低黏附性癌(低分化腺癌，部分为印戒细胞癌)，侵出浆膜层，侵犯神经及脉管组织，手术标本下、上切端及另送(胃下切端)均未见癌浸润；找到胃小弯淋巴结0/18个，大弯及网膜淋巴结0/9个，幽门下淋巴结1/1个，幽门上淋巴结0/8个，见癌转移。小弯侧脂肪组织见少量胰腺组织”，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。术后分别于2016.7.13、2016.8.3、2016.8.23予“乐沙定200MGIVGTTQDD1+卡培他滨片1500MGPOBIDD1-14”方案化疗。于2016.09.21行回肠造口还纳术，术后恢复可，此次为行再次化疗就诊我院，门诊拟胃癌、直肠癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 108,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 176,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 187,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 205
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 239,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 231
},
{
"end_pos": 253,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 268,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 258
},
{
"end_pos": 283,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 273
},
{
"end_pos": 485,
"label_type": "药物",
"overlap": 0,
"start_pos": 481
},
{
"end_pos": 501,
"label_type": "药物",
"overlap": 0,
"start_pos": 498
},
{
"end_pos": 541,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 537
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2月余因“胃癌”于2015.11.27全麻上行“腹腔镜辅助上根治性全胃切除术（D2）”，术后病理回报（201543270），：（全胃），：胃体小弯侧浸润型管状腺癌II-III级，部分为粘液腺癌和低粘附性癌，侵及浆膜层，脉管内见癌栓。手术标本下、上切端及另送（下切端）未见癌浸润。找到贲门左淋巴结0/21个，小弯淋巴结11/13个，大弯淋巴结1/7个，幽门下淋巴结0/2个，幽门上淋巴结1/8个，另送（第7组）淋巴结3/4个，（第8组）淋巴结1/3个，（第9组）淋巴结7/7个，（第11组）淋巴结3/5个，（第12A组）淋巴结0/1个，（第12P组）淋巴结0/1个，见癌转移。，免疫组化：KI67（60%肿瘤细胞阳性），CK7（+），CK20（-），VILLIN（+++），CK18（+++），HER-2（-），CEA（+++），E-CADHERIN（+++），CD68（+++），CD163（-），CD34（+++），D2-40（+），CD31（+++），CD56（-），SYN（-），CGA（-）。于2015.12.23、2016.01.14日行“伊立替康240MGIVGTTD1+替吉奥60MGPOBIDD1-14”方案化疗。为求再次术后化疗就诊我院，门诊拟胃癌术后化疗收入院，下次出院以来，精神、睡眠、食欲差，大便，小便正常，体重无明显变化。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 25,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 43,
"label_type": "手术",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 47,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 303,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 294
},
{
"end_pos": 342,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 341
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者2-月前因诊断为升结肠恶性肿瘤及肝内外胆管结石行根治性左半结肠切除术+胆总管探查术。升结肠肿瘤病理类型：左半结肠溃疡型中分化管状乳头状腺癌，免疫组化 CK7（－） CK20（+++） CEA（++） VILLIN（+++） CDX－2（++） KI-67（+++）＞90% P53（+） CERBB-2（－） EGFR（+） GST－π（+） TOPOII（++） PGP（+） SYN（－） CGA（－） NSE（－） CD56（－） MLH－1（++） MSH－2（+++） MSH－6（+++） PMS－2（++）；分期T3N1M0。今可按照FOXFOL方案行第二次化疗。遂以“升结肠肿瘤根治术后2-月，拟行第2次化疗”收治入院。\U0004 患者自起病以来，精神可，胃纳可，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 39,
"label_type": "手术",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 55,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 129,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 163
},
{
"end_pos": 192,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
},
{
"end_pos": 233,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 224
},
{
"end_pos": 249,
"label_type": "药物",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 258,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 261,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 260
},
{
"end_pos": 300,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 284
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前4年因“乙状结肠癌”就诊我院，于我院行“腹腔镜辅助上乙状结肠癌根治术”，术中见“肿瘤位于乙状结肠中段，约3*2.5CM，对系膜侧侵出浆膜层，未侵犯周围组织，周围无明显肿大淋巴结”，术后病理(201131862)回报“(乙状)结肠蕈伞型管状腺癌II级，侵及浆膜层，手术标本下、上切端及另送(下、上切端)未见癌浸润，找到肠周淋巴结11个均未见癌转移，另送(肠系膜上动脉根部淋巴结)为脂肪脉管结缔组织”，术后病情恢复良好出院，后门诊定期复查发现肝、肺、骨多发转移。入院前2年前开始给予口服希罗达及中药治疗，无诉腹痛、腹胀，无畏冷、发热等不适。今为再次治疗，门诊拟“乙状结肠癌术后伴肝、肺骨多发转移”收治入院，自发病以来，饮食较差，睡眠可，二便正常，无消瘦乏力，体重较前无明显改变。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 50,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 91,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 147,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 240,
"label_type": "药物",
"overlap": 0,
"start_pos": 236
},
{
"end_pos": 243,
"label_type": "药物",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 260,
"label_type": "药物",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 314,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 309
},
{
"end_pos": 333,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 332
},
{
"end_pos": 336,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 335
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余诊为直肠癌，于2014年11月19日在全麻上行“腹腔镜上直肠癌根治术（MILES）”，手术顺利。术后病理(201440195），：“（直肠）直肠溃疡型管状腺癌II级并坏死，侵出外膜层，未侵及齿状线，侵犯神经组织，下、上切端及环周切缘均未见癌浸润。肿物周围淋巴结6个、肠周淋巴结14个未见癌转移。，病理分期：PT4AN0M0，IIB期。”术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。于2015年1月7日、2015年2月4日、2015年3月4日行“奥沙利铂（齐沙）250MGIVGTTD1+希罗达1500MGPOBIDD1-14”方案3次化疗，未见明显化疗副反应，今返院行第4周期化疗，门诊拟“直肠癌术后化疗”收入院。出院后饮食、睡眠可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 37,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 71,
"label_type": "手术",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 107,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 218,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 212
},
{
"end_pos": 336,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 324
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前5月余，以“排便次数增多伴血便1个月。”为主诉入院，诊断直肠癌，遂于2013-5-7在全麻上行腹腔镜上直肠癌根治术+预防性回肠造瘘，术顺，术后予防感染、补液等治疗。，病理示：1、大肠溃疡型管状腺癌II级，侵及深肌层，手术标本吻合切端见少量癌浸润，手术标本另一切端及另送（下切端）、（上切端）均未见癌浸润。找到肿物周淋巴结6个，肠周淋巴结9个均未见癌转移。另送（肠系膜上动脉根部淋巴结）为脂肪、脉管及神经组织。2、大肠管状腺瘤，伴低级别下皮内瘤变。，免疫组化结果：CK7（-），CK20（++），VILLIN（+++），CEA（+++），CDX-2（+++），CD56（-），KI67（50%+）。今患者再次入院，要求关闭造瘘口，门诊拟“直肠癌术后，回肠造瘘术后”收入院，自发病以来，精神、睡眠、食欲尚可，大便经造瘘口排出可，小便正常，体重无明显变化。 | |
[
{
"end_pos": 12,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 73,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 76,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 95,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 136,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 199,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 187
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于1月余前因“直肠癌”在我科行“腹腔镜上直肠癌根治术（MILES）+放射性粒子植入术”，手术顺利，术后病理结果为：（直肠）溃疡型中分化管状腺癌浸及肠壁深肌层，双切端未见癌累及，肠壁淋巴结见癌转移（1/10）。术后患者恢复较好，出院后患者无腹痛、腹胀，无畏寒发热，会阴部切口逐步愈合，现已明显变浅变小，肉芽组织生长良好，今患者为求术后第1次全身静脉化疗来我院就诊，门诊以“直肠癌（MILES）术后”收入我科。\U0004 患者发病以来，神志 清晰，精神可，胃纳可，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 25,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 32,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 40,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 79,
"label_type": "手术",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 148,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 146
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 169,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 167
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 172
},
{
"end_pos": 189,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 184
},
{
"end_pos": 199,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 212
},
{
"end_pos": 236,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 268,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 273,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 270
},
{
"end_pos": 279,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 277
},
{
"end_pos": 284,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 280
},
{
"end_pos": 288,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 285
},
{
"end_pos": 294,
"label_type": "手术",
"overlap": 0,
"start_pos": 289
},
{
"end_pos": 329,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 320
},
{
"end_pos": 334,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 332
},
{
"end_pos": 345,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 348,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 352,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 349
},
{
"end_pos": 367,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 365
},
{
"end_pos": 384,
"label_type": "药物",
"overlap": 0,
"start_pos": 382
},
{
"end_pos": 391,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 389
},
{
"end_pos": 403,
"label_type": "药物",
"overlap": 0,
"start_pos": 400
},
{
"end_pos": 447,
"label_type": "药物",
"overlap": 0,
"start_pos": 444
},
{
"end_pos": 450,
"label_type": "药物",
"overlap": 0,
"start_pos": 448
},
{
"end_pos": 461,
"label_type": "药物",
"overlap": 0,
"start_pos": 457
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于4月前（2015-09-07）因“1.盆腔包块（卵巢CA？）；2.糖尿病”在全麻上行剖腹探查+全子宫两附件切除+大网膜切除+阑尾切除+放射性粒子置入术。，术中见：右侧附件失去正常形态，大小约10X9X8CM，实性，表面充血水肿，呈紫蓝色，可见烂鱼肉样组织，质脆，易触血，侵及后盆壁，与宫底、乙状结肠形成粘连。钝性分离粘连后，见子宫常大，子宫底、前壁见转移癌灶。左侧输卵管见少量转移灶，左卵巢形态正常。大网膜增厚、盆腔腹膜见散状结节病灶，最大约3CM。术中切除右附件交家属过目后送病理行冰冻切片示“（右附件）卵巢浆液性乳头状囊腺癌浸及输卵管”，遂行子宫、左侧附件、大网膜、阑尾切除术后标本送病检，，术后病检示：1、（肿瘤组织）送检物为浆液性乳头状囊腺癌。2、子宫表面见癌组织累及，宫腔、宫颈及右附件均未见癌累及。3、大网膜及阑尾均未见癌转移。并于09-11行顺铂100MG腹腔灌注、09-15行紫杉醇210MG静滴第一次化疗。分别于2015-10-20、2015-12-01予患者行紫杉醇（特素)210MG+奥沙利铂180MG化疗2个疗程，化疗过程较为顺利，患者恶心、呕吐等不适症状较轻。现患者无特殊不适，要求行第四次化疗。\U0004 患者本次发病以来，食欲正常， 神志清醒，精神尚可，睡眠尚可，大便正常，小便正常，体重无明显变化。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 14,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 62,
"label_type": "手术",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 86,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 145,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 131
},
{
"end_pos": 157,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 151
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 250,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 246
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者3月前因“反复腹痛、腹泻10余天，加重3天”入院，于2016-03-18在全麻上行乙状结肠部分切除+乙状结肠单腔造瘘术，手术过程顺利。，术后病理：结肠腺癌（中度分化），浸润溃疡型，体积5*4*0.9CM，侵达浆膜脂肪组织。双端切线及环周底部切除面未查见癌。肠壁一站（8/14个）淋巴结癌转移。符合结肠炎性息肉。，免疫组化染色示癌组织：SYN（-）、TS弱（+）。2月前患者造口旁出现可复性肿物，站立和用力后增大，平卧后可以回纳消失，伴造口脱垂及肠粘膜渗血，现患者为求进一步诊治，门诊以“造口旁疝”收入我科。 患者精神欠佳，普通饮食，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 19,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 73,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 86,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 175,
"label_type": "药物",
"overlap": 0,
"start_pos": 172
},
{
"end_pos": 185,
"label_type": "药物",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 197,
"label_type": "药物",
"overlap": 0,
"start_pos": 193
},
{
"end_pos": 209,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 258,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 251
},
{
"end_pos": 282,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 285,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 284
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月余于我院诊为回盲部肿瘤，于2013-12-10在全麻上行根治性左半结肠切除术，术后病理（201339034）示回盲部浸润型粘液腺癌，侵犯浆膜外，手术标本回肠切端、结肠切端均未见癌浸润，送检淋巴结未见癌转移，术后给予对症、营养支持等治疗，术后恢复良好,伤口愈合II/甲，术后于2014.01.02，行化疗治疗：FOLFOX，方案：替加氟3.4持续泵入/CF0.3D1-2+奥沙利铂200MGD1，辅以保肝、制酸、止吐、提高免疫力，化疗过程顺利，无明显化疗不良反应，今为再次化疗入院，门诊拟回盲部腺癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 11,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 40,
"label_type": "手术",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 75,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 259,
"label_type": "药物",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 272,
"label_type": "药物",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 280,
"label_type": "药物",
"overlap": 0,
"start_pos": 277
},
{
"end_pos": 302,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 301
},
{
"end_pos": 305,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 304
},
{
"end_pos": 352,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 351
},
{
"end_pos": 359,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 358
},
{
"end_pos": 362,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 361
},
{
"end_pos": 384,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 383
},
{
"end_pos": 387,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 386
},
{
"end_pos": 421,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 414
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因患“乙状结肠癌”于2014-02-25于我院在全麻上予行乙状结肠癌根治术；术后病理(201402452），示：（乙状结肠）腺癌（中、低度分化），隆起型，面积3.5*2CM，侵达浆膜脂肪组织，双端切线及另送“近端切线”、“远端切线”未查见癌。一站（13个）、中间组（3个）、中央组（5个）淋巴结未查见癌。，免疫组化染色示癌组织：ERCC1少数（+）、TS（-）。，病理分期为：PT3N0M0 IIA期 DUKESB。依情行术后辅助化疗指证存在，排除化疗禁忌后，先后给予6个周期辅助化疗，，具体化疗方案为：奥沙利铂150MG D1，亚叶酸钙0.3G+替加氟1.0G D2-D6，同时给予升白细胞、保肝、护胃、止吐、免疫增强治疗。自下次出院后，患者一般情况保持良好，无乏力感，无发热，无恶心、呕吐，无胸闷、心慌，无头晕、头痛，无反酸、嗳气，无明显进食不适，未现明显腹痛、腹胀；大小便情况良好。现患者为行复查来我院就诊，门诊以“乙状结肠癌术后”收入院。目前患者精神及情绪状态可，食欲、饮食好，夜间睡眠可，大小便正常，近期无明显体重变化。 | |
[
{
"end_pos": 9,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 79,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 120,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 119
},
{
"end_pos": 143,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 155,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 204,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 202
},
{
"end_pos": 229,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 235,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 234
},
{
"end_pos": 236,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 241,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 240
},
{
"end_pos": 266,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 279,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 278
},
{
"end_pos": 315,
"label_type": "手术",
"overlap": 0,
"start_pos": 303
},
{
"end_pos": 332,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 331
},
{
"end_pos": 335,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 334
},
{
"end_pos": 383,
"label_type": "药物",
"overlap": 0,
"start_pos": 379
},
{
"end_pos": 400,
"label_type": "药物",
"overlap": 0,
"start_pos": 396
},
{
"end_pos": 418,
"label_type": "药物",
"overlap": 0,
"start_pos": 415
},
{
"end_pos": 473,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 472
},
{
"end_pos": 476,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 475
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于3月前因残胃癌在我院于2014年01月02日在全麻上行根治性残胃癌切除术手术顺利。术后病理示（残胃）胃近贲门处溃疡型管状腺癌II-III级，部分为粘液腺癌，侵及浆膜层，侵犯神经，脉管内见癌栓，未见侵犯食管胃交界区。手术标本下切端、吻合肠管双切端及另送（下切端）均未见癌浸润，找到贲门**/8个，小弯侧淋巴结0/6个，大弯侧淋巴结0/2个，见癌转移。术后恢复良好，顺利出院。出院后于术后2周出现“腹痛伴肛门停止排气、排便”再次就诊我院，考虑“粘连性小肠梗阻”予禁食、胃肠减压、灌肠、抑制消化液分泌、营养支持等积极保守治疗后，患者腹痛一度好转后再次呈持续性腹痛伴阵发性加剧，遂于2014.1.25全麻上行“剖腹探查+小肠粘连松解术”，术顺，术后恢复良好，出院后无腹痛、腹胀、恶心、呕吐等不适，2014.02.17、2014.3.3、2014.4.1于我院行“奥沙利铂100MGD1IVGTT+亚叶酸钙200MGD1-2IVGTT+替加氟3.0GCIV”方案术后3周期化疗，化疗过程顺利，无特殊不适，此次为化疗再次入院。患者出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 59,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 120,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 156,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 151
},
{
"end_pos": 167,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 172
},
{
"end_pos": 189,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 208,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 198
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 213
},
{
"end_pos": 267,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 262
},
{
"end_pos": 289,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 288
},
{
"end_pos": 292,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 291
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊为胃角癌，2015年09月07日在全麻上行腹腔镜辅助上根治性远端胃大部切除术（毕II式，D2），术后予预防性抗感染、制酸、补液支持等治疗。术后病理（201532192），：(远端胃大部分)，:胃角溃疡型管状腺癌II级，侵及浆膜层，手术标本双切端及另送(下切端)均未见癌浸润。找到小弯淋巴结2/21个、大弯淋巴结0/2个、幽门下淋巴结0/2个、幽门上淋巴结1/11个，及另送(胃右A根部）淋巴结0/3个、(第8P）淋巴结1/6个，见癌转移。术后恢复良好,伤口愈合II/甲。此次为化疗再次就诊我院，门诊拟胃角癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 27,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 66,
"label_type": "手术",
"overlap": 0,
"start_pos": 42
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 100,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 132,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 150,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 200,
"label_type": "手术",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 220
},
{
"end_pos": 252,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 266,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 324,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 319
},
{
"end_pos": 357,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 467,
"label_type": "药物",
"overlap": 0,
"start_pos": 463
},
{
"end_pos": 484,
"label_type": "药物",
"overlap": 0,
"start_pos": 480
},
{
"end_pos": 503,
"label_type": "药物",
"overlap": 0,
"start_pos": 501
},
{
"end_pos": 509,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 507
},
{
"end_pos": 536,
"label_type": "药物",
"overlap": 0,
"start_pos": 532
},
{
"end_pos": 553,
"label_type": "药物",
"overlap": 0,
"start_pos": 549
},
{
"end_pos": 597,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 592
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前5月余于我院诊断为“直肠癌伴两肺多发转移瘤”，予2016-07-08行“腹腔镜上直肠部分切除术（姑息性）+乙状结肠造瘘术”，，术中见：腹腔内无明显出血，没有明显粘连，无腹水，肿瘤下缘位于腹膜反折下2CM右左，明显累及浆膜面，侵犯左侧盆壁，肿瘤上缘于腹腔内不可探及，术中诊断“直肠癌伴肺转移”，考虑肿瘤晚期，外侵明显，遂决定行“腹腔镜上姑息性直肠癌切除术（HARTMANN）+乙状结肠造瘘术”。术顺，术后予止血、止痛，抑酸保胃、保肝，增强免疫，加强营养支持等治疗，恢复良好。，术后病理示：(直肠)，：肠溃疡型管状腺癌II级，部分为筛状粉刺型，伴坏死，侵犯神经及脉管，见脉管内癌栓，侵及浆膜层。手术标本下、上切端均未见癌浸润。找到肠周淋巴结2/12个，见癌转移，找到癌结节3个。另送(肠系膜上动脉根部淋巴结)镜上为脂肪、血管及纤维结缔组织。，免疫组化染色结果：KI67（80%阳性），EGFR（+），P53（+），P16（+）。于2016.07.30、2016.8.20、2016.09.10、2016.10.14行“伊立替康240MGIVGTTD1+卡培他滨1500MGPOBIDD1-14+洛铂40MG腹腔灌注D1”方案化疗。于2016.11.12予“伊立替康240MGIVGTTD1+卡培他滨1500MGPOBIDD1-14”方案化疗，今为第6次化疗，就诊我院，门诊拟“直肠癌术后化疗”收入院。自下次发病以来，精神、睡眠、食欲尚可，大便如下述，小便如常，体重无明显变化。 | |
[
{
"end_pos": 25,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 43,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 76,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 123,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 186,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 178
},
{
"end_pos": 201,
"label_type": "手术",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 222,
"label_type": "药物",
"overlap": 0,
"start_pos": 219
},
{
"end_pos": 225,
"label_type": "药物",
"overlap": 0,
"start_pos": 223
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者5个半月前(2014-12-23)因“直肠癌”，在我院全麻上上行直肠高位前切除术。术中探查H0P0，病灶大小约3*2.5*1.0CM，位于直肠下段，左前壁，浆膜为脂肪遮盖。余腹膜内未见异常。，术后病理：，进展期直肠癌：隆起型 中分化管状腺癌 断端无癌。淋巴结见转移癌（1/15枚）DUKES分期C期（，病理号：178036），术后3周（4个半月前）因胆囊炎、胆囊结石，在我院普外科行急诊胆囊切除术。恢复顺利，2015-5-4于我科行希罗达、艾恒化疗一次，现为再次行化疗而入我科，患者病来食欲佳，睡眠良好，大便不成形，小便正常，近半年自觉体重上降。 | |
[
{
"end_pos": 6,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 3
},
{
"end_pos": 36,
"label_type": "手术",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 46,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 57,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 56
},
{
"end_pos": 61,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 68,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 66
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 158,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 151
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 190
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 201
},
{
"end_pos": 370,
"label_type": "药物",
"overlap": 0,
"start_pos": 366
},
{
"end_pos": 383,
"label_type": "药物",
"overlap": 0,
"start_pos": 379
},
{
"end_pos": 397,
"label_type": "药物",
"overlap": 0,
"start_pos": 394
},
{
"end_pos": 459,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 453
},
{
"end_pos": 465,
"label_type": "药物",
"overlap": 0,
"start_pos": 463
},
{
"end_pos": 535,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 534
},
{
"end_pos": 538,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 537
},
{
"end_pos": 581,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 574
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，罹患残胃癌于2013-9-6在我院予行全麻上全胃切除术（空肠J字代胃）；，术中探查见：腹腔内严重粘连，腹腔内无腹水，肝脏无法探查，盆底腹膜无异常；肿瘤位于残胃后壁，溃疡性肿块，约10 X 8CM。肿瘤侵出浆膜层。患者术后积极予相关对症支持治疗并恢复顺利良好。相关手术病理(2013 11248），示：残胃低分化腺癌，体积7.5*7*3.2CM，蕈伞型，侵达浆膜。双端切线及另送“胃远端切线”未查见癌。贲门周围（10个）淋巴结未查见癌。，免疫组化染色示癌组织：ERCC1（+）、β-TUBULIN-III（+）、TS（-）、RRM1（-）、TOPOII（阳性数60%）、CERBB-2（-）。合患者病情及肿瘤病理与分期继续予行术后化疗相关辅助治疗指征存在；依情先后予2013-9、2013-10予行术后辅助化疗2周期，，具体用药为：奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1000MG D2-6 静滴，同时辅以镇吐、升血、免疫调节等对症支持治疗（化疗期间患者总体耐受性良好；复查血像示外周血白细胞减少，予瑞白升血处理）。自下次出院（2013-10-23）以来，患者一般情况保持良好；无发热，无恶心、呕吐，无明显反酸、嗳气，无明显进食不适，未现明显腹痛、腹胀。现患者为行规律性复查并完善相关后续辅助治疗而再至我科就诊，遂依情以“胃恶性肿瘤术后”收入院。目前患者精神及情绪状态良好，食欲、饮食好，夜间睡眠后；近期无明显体重变化。 | |
[
{
"end_pos": 30,
"label_type": "手术",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 44,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 43
},
{
"end_pos": 64,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2016-11-04在全麻上行\"胃癌根治术(全胃）\"，，术后病理回报:“（胃大体）镜检为中至低分化腺癌，LAUREN，分型：肠型，癌组织侵犯至胃壁浆膜上层，并累及食管壁外膜层；未见明确脉管内癌栓，可见神经束侵犯；网膜组织未见癌。淋巴结41枚，2枚见癌。（远、近切缘）未见癌”。术后预防感染、抑制分泌、静脉营养等对症支持处理，恢复好，2016-12-05已予行一程术后辅助化疗，以现为行上一程化疗收住我科，起病以来，患者精神尚可，食欲欠佳，大小便正常，体重上降3KG。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 139,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 144
},
{
"end_pos": 159,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 181,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 241,
"label_type": "药物",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 250,
"label_type": "药物",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 286,
"label_type": "药物",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 295,
"label_type": "药物",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 331,
"label_type": "药物",
"overlap": 0,
"start_pos": 327
},
{
"end_pos": 340,
"label_type": "药物",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 372,
"label_type": "药物",
"overlap": 0,
"start_pos": 369
},
{
"end_pos": 380,
"label_type": "药物",
"overlap": 0,
"start_pos": 378
},
{
"end_pos": 411,
"label_type": "药物",
"overlap": 0,
"start_pos": 408
},
{
"end_pos": 420,
"label_type": "药物",
"overlap": 0,
"start_pos": 417
},
{
"end_pos": 455,
"label_type": "药物",
"overlap": 0,
"start_pos": 452
},
{
"end_pos": 485,
"label_type": "药物",
"overlap": 0,
"start_pos": 481
},
{
"end_pos": 500,
"label_type": "药物",
"overlap": 0,
"start_pos": 497
},
{
"end_pos": 537,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 533
},
{
"end_pos": 562,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 561
},
{
"end_pos": 565,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 564
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前1余年前于我院诊为胃癌，于2012-08-07在全麻上行根治术全胃切除术。术后病理（201223223）示全胃：食管胃交界溃疡型管状腺癌，II-III级，侵出浆膜层，侵犯脉管和神经。手术标本下切端见癌浸润，手术标本上切端和另送（下切端）未见癌浸润。镜上找到贲门周淋巴结3/8个、小弯淋巴结3/4个、大弯淋巴结0/1个、幽门下淋巴结0/4个和幽门上淋巴结0/1个见癌转移。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲，并顺利出院，2012.09.24行“伊立替康280MG+替吉奥60MGBID×14D”方案化疗1周期，2012.10.23按“伊立替康280MG+替吉奥40MGBID×14D”方案化疗1周期，2012.11.20按“伊立替康240MG+替吉奥80MGBID×7D”化疗1次,2012.12.22按““安素泰210MG+艾奕40MGBID×14D”化疗1次，2013.1.18予“安素泰240MG+替吉奥40MGBID×14D”方案化疗1次，2013.02.23按T“安素泰240MG”方案化疗1周期。2014.08.28予“表柔比星70MGIVGTTD1+替吉奥40MGBID×10D”方案化疗1次。今为再次化疗就诊我院，门诊拟胃癌术后化疗后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 48,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 55,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 61,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 81,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 132,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 131
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 161,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 171,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 196,
"label_type": "手术",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 229,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 239,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 238
},
{
"end_pos": 291,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 286
},
{
"end_pos": 312,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 300
},
{
"end_pos": 416,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 410
},
{
"end_pos": 502,
"label_type": "药物",
"overlap": 0,
"start_pos": 498
},
{
"end_pos": 518,
"label_type": "药物",
"overlap": 0,
"start_pos": 515
},
{
"end_pos": 532,
"label_type": "药物",
"overlap": 0,
"start_pos": 528
},
{
"end_pos": 580,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 575
},
{
"end_pos": 602,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 601
},
{
"end_pos": 605,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 604
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊为直肠癌，于2014-03-03在全麻上行腹腔镜上直肠癌根治术DIXON，，术中见：腹腔网膜及盆底光滑无结节，无腹水，肝表面光滑，胃及空肠未见明显病变。直肠腹膜返折距离肛门约10CM可触及一肿物，大小约3CM*2CM，质硬，未侵犯浆膜层，肠系膜上动脉根部可触及多枚肿大，与腹壁明显粘连，予分离，见肠管周围数个肿大淋巴结，大者直径约1CM，决定行“腹腔镜直肠癌根治切除术”。。术后病理(201405649)示1.大肠溃疡型管状腺癌II级，侵犯浅肌层。周围肠管粘膜及粘膜上层淋巴组织增生活跃。手术标本双切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结1/18个，及另送（肠系膜上血管旁）淋巴结0/7个见癌转移。，免疫组化结果：CK7（-），CK20（+），VILLIN（+++），CEA（+++），CDX-2（+++），CGA（-），CD56（-），SY（-），KI67（60%+）。2.大肠管状腺瘤，伴低级别下皮内瘤变。，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。于2014.3.25、2014.4.9、2014.4.24、2014.5.14予“奥沙利铂150MGIVGTTD1+替加氟3.6GCIVD1+亚叶酸钙300MGIVGTTD1-2”方案行4次化疗，此次为术后第5次化疗再次就诊我院，门诊拟直肠癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 22,
"label_type": "手术",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 48,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 107
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 212,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 208
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者20余天月前行姑息性乙状结肠部分切除术，术后病理（201413928），：乙状结肠粘液腺癌，体积10*8*2.5CM，浸润溃疡型，侵达浆膜并侵穿纤维膜达脂肪组织。双端切线及另送“近切线”、“远切线”未查见癌。肠壁一站（7个）、中间组（6个）淋巴结未查见癌。，免疫组化染色示癌组织：TS大部分（+）、SYN（-）。患者于1天前开始出现腹胀、呕吐胃内容物，未排气、排便。急来我院门诊就诊，为行进一步诊治门诊依情以“结肠术后”收入院。患者自发病以来，无反复发热、畏寒，未现尿频、尿急、尿痛及排尿困难。目前精神差，不能进饮食。否认近期明显体重改变。 | |
[
{
"end_pos": 19,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 55,
"label_type": "手术",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 66,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 88,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 155,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 165,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 180
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 191
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 205
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 240,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 231
},
{
"end_pos": 254,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 364,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 356
},
{
"end_pos": 381,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 379
},
{
"end_pos": 386,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 384
},
{
"end_pos": 456,
"label_type": "药物",
"overlap": 0,
"start_pos": 452
},
{
"end_pos": 472,
"label_type": "药物",
"overlap": 0,
"start_pos": 469
},
{
"end_pos": 550,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 546
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前5月余于我院诊断为“贲门癌”，于2015-12-21在全麻上行腹腔镜上根治性全胃切除术+胆囊切除术。术后病理示1、（全胃），：食管胃交界溃疡型管状腺癌II-III级，侵出浆膜层，侵犯神经组织。手术标本下切端见癌浸润。手术标本上切端及另送（下切端）均未见癌浸润。找到贲门左淋巴结4/9个，贲门右淋巴结0/1个，小弯淋巴结1/1个，大弯淋巴结0/0个，幽门下淋巴结0/3个，幽门上淋巴结0/1个，及另送（第7组）淋巴结1/1个，（第8组）淋巴结0/1个，（第11组）淋巴结2/3个，（第12组）淋巴结0/6个，见癌转移。，免疫组化：KI67（80%肿瘤细胞阳性），CK7（++），CK20（-），VILLIN（+++），CEA（+++），CD56（-），CGA（-），SYN（-），HER-2（-）。2、（第9组淋巴结），：送检脂肪及脉管组织。3、（胆囊），：胆囊组织。术后恢复可，于2016.01.21、2016.02.14、2016.03.08、2016.04.01、2016.04.28予“伊立替康240MGIVGTTD1+替吉奥40MGPOBIDD1-14”方案化疗，辅以止吐、增强免疫、营养支持等治疗，化疗过程顺利，无化疗副反应。今为行第6周期化疗，求诊于我院门诊，门诊拟“贲门腺癌（PT4AN3M0，IIIC期）术后化疗”收入院。自下次出院以来精神、睡眠、饮食可，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 56,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 102,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 147,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 145
},
{
"end_pos": 148,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 157
},
{
"end_pos": 162,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 161
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 196,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 191
},
{
"end_pos": 245,
"label_type": "药物",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 258,
"label_type": "药物",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 272,
"label_type": "药物",
"overlap": 0,
"start_pos": 269
},
{
"end_pos": 298,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 297
},
{
"end_pos": 347,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 349,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 348
},
{
"end_pos": 380,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 373
},
{
"end_pos": 389,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 381
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者约于3年前因“乙状结肠癌”于2014-02-19日在全麻上行乙状结肠部分切除、乙状结肠单腔造瘘，阑尾切除术。手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好。，术后病理：结肠腺癌(中低度分化),浸润溃疡型,面积2.2*1.2CM，侵达浆膜，少数脉管内查见癌栓。双端切线未查见癌。结肠肠壁部分坏死、穿孔，肠系膜及肠壁周围脂肪组织化脓、坏死。肠壁一站（3个）淋巴结未查见癌。慢性阑尾炎。，免疫组化染色示癌组织：ERCC1（+）、TS（+）。术后给予患者化疗4周期，，方案为：奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1000MG D2-6 静滴，同时给与升白细胞、护肝、止吐、免疫增强治疗，患者化疗过程平稳。后患者拒绝继续化疗，未规律复查。院外期间，患者无发热，无腹痛腹胀不适，大便通畅。现患者为行复查来我科就诊，以“乙状结肠癌术后、乙状结肠造瘘术后”收入院。 病人自下次出院以来，神志清，精神可，饮食可，大、小便正常，体重未见明显变化。 | |
[
{
"end_pos": 10,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 28,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 37,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 45,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 63,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 76,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 90,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 98,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 104,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 110,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 112,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 111
},
{
"end_pos": 118,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 116
},
{
"end_pos": 137,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 152,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 163,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 202,
"label_type": "手术",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 232,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 221
},
{
"end_pos": 295,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 284
},
{
"end_pos": 330,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 299
},
{
"end_pos": 439,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 435
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者1月前因“腹部不适伴黑便1月余”入院，，腰骶部平扫示：腰1压缩性骨折，，腰椎退行性变：腰2/3、3/4、4/5椎间盘突出并腰4/5水平双侧隐窝狭窄，骶1-3水平椎管局限性膨大，不除外骶管囊肿。，腹部CT示：胆囊结石，胃腔扩张、幽门部周围壁厚。，行胃镜示：胃癌伴幽门梗阻；，病理示：（胃窦、幽门）腺癌。 ，幽门螺旋杆菌染色示：阳性（1+）。于2016-04-12全麻上行根治性胃大部切除+毕I式吻合术。，术后病理示：（201607470）胃窦腺癌（中低度分化），浸润溃疡型，体积4*4*2CM，侵达浆膜脂肪组织，部分侵穿浆膜。双端切线及另送“远端”切线未查见癌。呈六组（2/9个）淋巴结癌转移。三组（2个）、四组（3个）、另送“1、3、7组”（6个）淋巴结未查见癌。，免疫组化染色示癌组织：CERBB-2（-）、SYN（-）、β-TUBULIN-III部分（+）、TS部分弱（+）、RRM1部分（+）、TOPOII部分（+）。患者为求进一步诊治，来我院就诊，门诊以“胃癌术后”收入院。 发病以来，食欲差，睡眠可，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 37,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 27
},
{
"end_pos": 47,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 88,
"label_type": "手术",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 130,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 119
},
{
"end_pos": 138,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 137
},
{
"end_pos": 192,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 208,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 202
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 244,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 242
},
{
"end_pos": 278,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 302,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 294
},
{
"end_pos": 309,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 305
},
{
"end_pos": 316,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 323,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 319
},
{
"end_pos": 372,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 371
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者6周前因“血便伴大便习惯改变1月余”,确诊为“1、乙状结肠腺癌并肝转移2、两肺结节 转移瘤？”后，完善检查，无手术禁忌症，于2013-12-27全麻上行姑息性“乙状结肠切除”，术顺，术后恢复可，术后病理结果回示：1（乙状结肠） 镜检为结肠中至低分化管状腺癌，癌组织浸润至肠壁浆膜层外脂肪结缔组织，可见神经束侵犯及脉管内癌栓。2（近切缘）未见癌。3（远切缘）未见癌。4（中央组淋巴结）4枚，未见癌。5（中间组淋巴结）2枚，未见癌，另见2枚肿瘤种植结节。6（肠周淋巴结）6枚，1/6见腺癌转移。术后预防感染、对症、支持治疗，术后诊断1.乙状结肠腺癌并肝转移 PT4AN1M1 IV期;2.两肺结节 转移瘤？3.子宫肌瘤4.慢性胆囊炎 5.左肾囊肿。现术后第6周，今为进一步治疗遂入我科。患者现无发热、乏力、咳嗽、气促、身目黄染等，精神睡眠可，胃纳一般，大小便可，体重无明显上降。 | |
[
{
"end_pos": 10,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 88,
"label_type": "手术",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 110,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 147,
"label_type": "药物",
"overlap": 0,
"start_pos": 144
},
{
"end_pos": 152,
"label_type": "药物",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 155,
"label_type": "药物",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 166,
"label_type": "药物",
"overlap": 0,
"start_pos": 163
},
{
"end_pos": 182,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 180
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 247,
"label_type": "药物",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 251,
"label_type": "药物",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 258,
"label_type": "药物",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 261,
"label_type": "药物",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 297,
"label_type": "手术",
"overlap": 0,
"start_pos": 288
},
{
"end_pos": 335,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 334
},
{
"end_pos": 338,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 337
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者因\"体检发现肝占位10天\"于2012年1月到我院就诊，经完善检查诊断为结肠腺癌并肝多发转移,无手术禁忌症，于2012-02-06日全麻上行“DIXON'S+肠粘连松解术”，术顺，术后恢复顺利。术后病理示中分化腺癌，浸润至浆膜上，淋巴结3/9转移。于术后3周始返院行FOLFIRI（开普拓+5-FU/CF）化疗8周期，加安维汀7周期。2012-6-20查CT示肝脏各叶可见多发异常密度影，病变较前缩小（最大者由20×31MM缩至15×28MM），病变数目大致同前。多学科讨论决定暂停开普拓及安维汀，继续予5FU/CF维持化疗，结合射频治疗。后患者于2012年7月11日行肝转移瘤射频消融术，术程顺利。现为进一步治疗入住我科，患者精神、饮食、睡眠可，大小便正常，无腹痛、腹胀、恶心、呕吐，体重无明显减轻。 | |
[
{
"end_pos": 31,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 27
},
{
"end_pos": 79,
"label_type": "手术",
"overlap": 0,
"start_pos": 56
},
{
"end_pos": 109,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 107
},
{
"end_pos": 112,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 128,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 192,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 210,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 224,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 239,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 254,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 270,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 325,
"label_type": "药物",
"overlap": 0,
"start_pos": 323
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 334
},
{
"end_pos": 340,
"label_type": "药物",
"overlap": 0,
"start_pos": 338
},
{
"end_pos": 357,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 356
},
{
"end_pos": 360,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 403,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 398
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于3月前因“反复进食受阻2月余。”为主诉入院，诊断食管占位，排除手术禁忌症后于2016-01-20在全麻上行胸腔镜上全胸段食管切除+食管-胃底右颈部吻合术，术顺，术后恢复可，术后病理（201602316），：(食管及胃底)，：食管溃疡型鳞状细胞癌II级，侵及外膜层，手术标本下、上切端均未见癌浸润，找到胃周淋巴结1/17个，另送(隆突上)淋巴结0/2个、(右喉返喉返神经旁)淋巴结0/8个、(左喉返喉返神经旁)淋巴结个0/5、(右锁骨下)淋巴结0/4个、(下段食管旁)淋巴结0/1个、(颈段食管旁)淋巴结0/2个、(上段食管旁)个淋巴结0/1个，见癌转移。排除化疗禁忌症后于2016.02.19、2016.03.13、2016.04.08以“顺铂40MGD1-2，紫杉醇（泰素）180MGD2”行化疗，辅以保肝、护胃、提高免疫力等处理，未见明显化疗副反应，现为求第4期化疗，就诊我院，门诊拟“食管癌术后化疗后”收住入院，自出院以来，精神、睡眠、饮食一般，大小便如常，体重无明显增减。 | |
[
{
"end_pos": 12,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 66,
"label_type": "手术",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 119,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 140,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 156,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 151
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 172
},
{
"end_pos": 221,
"label_type": "药物",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 226,
"label_type": "药物",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 371,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 367
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。入院前5+月，患者因胃癌于2014.5.21全麻上行腹腔镜胃癌根治术中转开腹全胃切除空肠食管ROUX-ENY吻合术+横结肠部分切除术。术后抗感染补液及营养支持治疗。术后病检：（1404047）<胃>低分化腺癌，部分为印戒细胞癌，侵及全层，双侧切缘未见癌累及，大弯淋巴结未见癌转移(0/3),小弯淋巴结见癌转移(10/15),<7、8、9组>淋巴结见癌转移(8/9)，大网膜组织未见癌累及，经科内讨论于6月2日行奥沙利铂+氟尿嘧啶化疗及对症治疗。2014年07月03日患者行术后第二次化疗，2014年08月18日患者行术后第三次化疗，2014年09月25日患者行术后四次化疗，患者化疗副反应较轻，化疗后精神、食欲、睡眠尚可，未有发热，未明显见脱发，无咳嗽、咳痰，今日患者为拟行第5次化疗，到我院门诊就诊，门诊以“胃癌术后第5次化疗”收入我科住院治疗。 | |
[
{
"end_pos": 15,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 27,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 65,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 91,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 111,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 146,
"label_type": "手术",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 204,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 402,
"label_type": "药物",
"overlap": 0,
"start_pos": 398
},
{
"end_pos": 418,
"label_type": "药物",
"overlap": 0,
"start_pos": 415
},
{
"end_pos": 477,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 476
},
{
"end_pos": 480,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 479
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于3个月前于我院查腹部CT示：1、横结肠近脾区肠壁增厚，伴邻近脂肪间隙内数个淋巴结，考虑新生物可能，建议进一步肠镜检查。2、肝内多发占位性病变，考虑多发转移瘤。，行肠镜示：结肠癌，病理回报为（降结肠）大肠管状腺癌II级。于2013年11月21日在全麻上行“腹腔镜辅助上姑息性右半结肠切除术”，手术顺利。术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。术后病理示“（右半结肠）大肠隆起型管状腺癌II级，侵出浆膜层，浆膜面见癌结节形成，脉管内见癌栓，手术标本双切端均未见癌浸润。找到肠周淋巴结4/18个见癌转移。，免疫组化结果：CK20（++），CK7（-），VILLIN（+++），CEA（+++），CDX-2（+++），CGA（-），SY（-），CD56（-），KI67（40%+）。”根据术后病理，肿瘤分期为PT4BN2AM1IV期。据其肿瘤分期有化疗指征，于2013-12-06以“伊立替康280MGIVGTTD1+替吉奥60MGPOBIDD1-14”方案化疗，化疗过程顺利，无明显化疗副作用。此次为化疗再次入院。自出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 4,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 0
},
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 22,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 39,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 70,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 91,
"label_type": "手术",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 115,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 155,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 146
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 225,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 221
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。胃癌术后2年，外院检查提示左上腹包块，肾积水外院2014-4-17胃镜提示胃底体粘膜水肿，僵硬（BORRMANNIV）。活检病理为低分化腺癌，部分印戒。2014.4.30行胃癌根治术，术中不详，术后病理：胃小弯弥漫浸润性低分化腺癌，部分为印戒，3X3CM，侵润胃壁全层，切缘、大网膜无癌累及，小弯侧大弯侧淋巴结10枚无癌转移。HER-2( 0) 。现术后恢复可，可进少量半流食，进食后无明显不适，体重较术前上降约5KG近期检查发现左上腹肿块，左肾积水。 | |
[
{
"end_pos": 40,
"label_type": "手术",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 55,
"label_type": "手术",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 97,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 140,
"label_type": "手术",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 155,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 180,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 178
},
{
"end_pos": 198,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 228,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 221
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 232
},
{
"end_pos": 257,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 271,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 260
},
{
"end_pos": 278,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 285,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 329,
"label_type": "手术",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 353,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 382,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 371
},
{
"end_pos": 386,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 385
},
{
"end_pos": 412,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 406
},
{
"end_pos": 477,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 467
},
{
"end_pos": 505,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 504
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于4年余前在我科行剖腹探查+乙状结肠肿瘤切除＋近端造口、远端封闭+结肠减压，3年余前行乙状结肠造口还纳术，已于2012年8月完成FOLFRI化疗方案五次，2014年3月入院复查发现卵巢转移，遂行经腹全子宫+两附件切除术+阑尾切除术+大网膜切除+左侧淋巴结清扫术+盆腔粘连松解，术中冰冻病理结果示左卵巢腺癌；手术顺利，术后患者恢复可，半年前*****行CT检查后发现发现网膜及系膜多发肿瘤转移，遂行规范XELOX化疗4次。1月前，患者因“乙状结肠癌术后3年余，肛门停止排气排便7天”入院。，入院后全腹部增强CT提示：结肠CA伴卵巢转移术后改变，小肠梗阻，考虑末端回肠粘连狭窄所致可能。遂于2015-12-03在全麻上行剖腹探查+肠粘连松解+左半结肠切除术，手术顺利，，术中冰冻切片提示：（左半结肠）腺癌，双切端未见癌累及。，术后病理诊断：左半结肠中分化管状腺癌，浸及肠壁全层，脉管内见癌栓。双切端未见癌累及。肠壁下淋巴结未见癌转移（0/10）。患者入院前无发热、寒战，无恶心、呕吐，无反酸、嗳气，今为行第5次化疗前来我院，门诊拟“乙状结肠癌、卵巢转移”收入我科。\U0004 患者自起病以来，精神可，胃纳可，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 45,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 51
},
{
"end_pos": 70,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 123
},
{
"end_pos": 137,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 146,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 182,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 188,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 189
},
{
"end_pos": 240,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 243
},
{
"end_pos": 259,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 277,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 292,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 280
},
{
"end_pos": 307,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 302
},
{
"end_pos": 411,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 405
},
{
"end_pos": 433,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 432
},
{
"end_pos": 436,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 435
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊为回盲部癌，于2015-06-23在全麻上行腹腔镜上左半结肠切除术，，术中见：腹腔内无明显出血，无明显腹水，于回盲部见肿瘤，大小约6×5×4CM，累及回肠末端约3.0CM，侵出浆膜层，与周围组织无明显粘连，未形成梗阻，近端肠管无扩张，周围及肠系膜根部未见明显肿大淋巴结。术后病理（201523144）示(左半结肠)，：肠浸润性管状腺癌II级，侵犯回盲瓣及回肠，侵及浆膜层，见神经侵犯，手术标本双切端及另送（下切端）（上切端）均未见癌浸润，找到阑尾根部淋巴结3个，回肠周淋巴结7个，结肠周围淋巴结26个，另送(回结肠动脉根部）淋巴结4个，(结肠中动脉根部）淋巴结4个，均未见癌转移；慢性阑尾炎。该病例未检测到KRAS基因12、13号密码子热点突变。该病例未检测到BRAF基因V600E突变。，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。此次为行第1次化疗再次就诊我院，门诊拟回盲部癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 10,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 52,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 127,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 111
},
{
"end_pos": 196,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 288,
"label_type": "药物",
"overlap": 0,
"start_pos": 284
},
{
"end_pos": 301,
"label_type": "药物",
"overlap": 0,
"start_pos": 297
},
{
"end_pos": 314,
"label_type": "药物",
"overlap": 0,
"start_pos": 310
},
{
"end_pos": 345,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 344
},
{
"end_pos": 374,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 373
},
{
"end_pos": 376,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 375
},
{
"end_pos": 406,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 402
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者4月前因“胃癌”于2017-05-04在我院于全麻上行胃癌癌根治术（远端胃大部切除+毕I式吻合术），手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好，切口愈合良好，病愈出院。，术后病理示：（201710017）胃窦前壁腺癌（低分化）粘液性印戒，面积5*4.5CM，厚1.2CM，侵达浆膜。双端切线未查见癌。三组（5个）、四组（4个）、七组（1个）、“1、3、7组”（12个）淋巴结，未查见癌。，免疫组化染色示：CERB-2（-）、SYN少量（+）、β-TUBULIN-III部分（+）、RRM1（-）、TOPO II少量（+），于我院行化疗，，化疗方案为：奥沙利铂200MG D1+亚叶酸钙0.3D2-6 +氟尿嘧啶750MG D2-6 静滴，同时予以升白细胞、止吐、抑酸、保肝、免疫增强治疗。 院外期间患者一般情况好，无恶心，无腹痛腹胀胀不适，现患者为行复查及化疗再次来院就诊，门诊以“胃癌术后”收入院。 近期患者一般情况良好，神志清，精神良好，饮食、睡眠良好，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 46,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 45
},
{
"end_pos": 50,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 51,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 57,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 56
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 93,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 120,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 141,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 208,
"label_type": "手术",
"overlap": 0,
"start_pos": 200
},
{
"end_pos": 230,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 251,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 236
},
{
"end_pos": 266,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 327,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 326
},
{
"end_pos": 344,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 342
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者3月余前无明显诱因出现下腹部疼隐痛，程度轻微，可自行忍受，予抑酸等处理后疼痛可缓解，腹痛无向腰背部放射，无腹胀、腹泻，无恶心、呕吐，无便血、黑便。遂就诊于我院，，查胃镜示：胃窦幽门前见一溃疡型肿物，胃窦腔变形，狭窄。，活检提示：（胃窦幽门前溃疡型肿物活检）镜检为中至低分化腺癌，LAUREN，分型：考虑混合型。入院后完善相关检查，未见明显手术禁忌，有手术适应症，于2017-04-07在我院行“腹腔镜胃癌根治术”，术程顺利，术后恢复良好。，病理检查：（胃大体）镜检为胃中至低分化腺癌，LAUREN，分型：混合型，癌组织浸润至胃壁浆膜层，可见脉管内癌栓及神经束侵犯；网膜组织未见癌。（近切缘）（远切缘），镜上：粘膜慢性炎，局灶腺体伴轻度不典型增生及肠下皮化生。（淋巴结）6/52见腺癌转移；，免疫组化：VEGF（局灶弱+），HER-2（0），CK（+）。，原位杂交：EBERS（-）。术后分期为T4N2M0 IIIB期，术后恢复可，双便正常，体重上降20+斤。术后于2017-05-04行XELOX方案化疗1程，现按主诊教授意见收入我科。 | |
[
{
"end_pos": 7,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 28,
"label_type": "手术",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 48,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 142,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 122
},
{
"end_pos": 151,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 156
},
{
"end_pos": 285,
"label_type": "药物",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 298,
"label_type": "药物",
"overlap": 0,
"start_pos": 294
},
{
"end_pos": 311,
"label_type": "药物",
"overlap": 0,
"start_pos": 308
},
{
"end_pos": 356,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 349
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“胃癌”于2015-5-19于我院行“胃癌根治术”，术后恢复良好，，术后病理示：胃窦腺癌，中度分化，浸润溃疡型，体积8*5*2.2CM，侵穿浆膜，部分脉管内查见癌栓，并大弯侧、小弯侧脂肪组织内及大网膜内多灶性癌转移，双端切线未查见癌。呈四组（3/9个）、六组（1/6个）淋巴结癌转移及“肝圆韧带”癌转移。三组（2个）、五组（1个）、“1、3、7组”（13个）淋巴结未查见癌。，癌组织免疫组化染色示：β-TUBULIN-III局灶（+）、TS（-）、RRM1局灶（+）、TOPOII少数（+）、CERBB-2（-）、SYN（-）。，依情予行术后2疗程化疗：奥沙利铂150MG D1+亚叶酸钙0.3G D2-6+替加氟1GD2-6,化疗过程顺利，无明显不适，现为进一步治疗至我科就诊，遂依情以“胃恶性肿瘤术后”收入院。发病来，患者目前患者精神好，食欲一般，夜间睡眠可，小便正常，大便未诉异常，近期体重无明显上降。 | |
[
{
"end_pos": 10,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 129,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 254,
"label_type": "药物",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 267,
"label_type": "药物",
"overlap": 0,
"start_pos": 263
},
{
"end_pos": 275,
"label_type": "药物",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 297,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 296
},
{
"end_pos": 336,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 335
},
{
"end_pos": 338,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 371,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 364
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“乙状结肠癌”于2012-11-30在我院于全麻上行乙状结肠癌根治术，手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好，切口愈合良好。，术后病理示：（13304.2012）(乙状结肠）腺癌（中度分化，部分为粘液腺癌图像），符合绒毛状管状腺瘤癌变，面积为4*3.5CM，侵穿浆膜，双侧切线及另送“近端”、“远端”切线未查见癌。一站淋巴结（9个）、中间组淋巴结（7个）未查见癌。查无化疗禁忌后，分别于2012-12-20、2013-1-21、2013-2-16行3次化疗治疗，，化疗方案为：奥沙利铂150MG D1，亚叶酸钙0.3G+替加氟1.0G D2-D6，同时给与升白细胞、护肝、止吐、免疫增强治疗，患者副反应轻。 院外期间患者一般情况好，无恶心，无腹痛腹胀胀不适，现患者为行复查及化疗再次来院就诊，门诊以“乙状结肠癌术后”收入院。 近期患者精神可，饮食可，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 24,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 57,
"label_type": "手术",
"overlap": 0,
"start_pos": 43
},
{
"end_pos": 82,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 97,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 106,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 194,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 209,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 349,
"label_type": "药物",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 366,
"label_type": "药物",
"overlap": 0,
"start_pos": 362
},
{
"end_pos": 383,
"label_type": "药物",
"overlap": 0,
"start_pos": 379
},
{
"end_pos": 400,
"label_type": "药物",
"overlap": 0,
"start_pos": 396
},
{
"end_pos": 463,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 458
},
{
"end_pos": 485,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 484
},
{
"end_pos": 488,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 487
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院1月余前于我院诊为降结肠中分化管状腺癌，于2016年03月04日在全麻上行“腹腔镜上根治性右半结肠切除术”，术后病理（N201601905），：（右半结肠），：结肠溃疡型中分化管状腺癌，侵犯肠壁全层及肠周脂肪组织，侵犯神经、脉管组织，手术标本双切端及另送(上切端)均未见癌浸润,另送(下切端)浆膜外纤维脂肪组织中见癌浸润。找到肠周淋巴结5/15个见癌转移。另送(右结肠根部淋巴结)、(结肠中血管右支根部淋巴结)镜上为纤维、血管、脂肪组织。（MN20160037），：该病例未检测到BRAF基因V600E突变。（MN20160037），：该病例检测到KRAS基因12号密码子G12S突变。术顺安返，予预防性抗感染、制酸、提高免疫力、营养支持等治疗好转后出院。于2016.04.12予“安维汀200MGIVGTTD1+奥沙利铂120MGIVGTTD2+氟尿嘧啶3400MGCIV48H+亚叶酸钙300MGIVGTTD1-2”方案化疗1个周期，化疗过程顺利，化疗后未见明显不良反应。此次为化疗再次就诊我院，门诊拟结肠癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 25,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 57,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 92,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 112,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 117,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 141,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 155,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 202,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 195
},
{
"end_pos": 225,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 223
},
{
"end_pos": 233,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 228
},
{
"end_pos": 244,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 238
},
{
"end_pos": 260,
"label_type": "药物",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 263,
"label_type": "药物",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 279,
"label_type": "药物",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 299,
"label_type": "药物",
"overlap": 0,
"start_pos": 296
},
{
"end_pos": 307,
"label_type": "药物",
"overlap": 0,
"start_pos": 305
},
{
"end_pos": 378,
"label_type": "药物",
"overlap": 0,
"start_pos": 376
},
{
"end_pos": 391,
"label_type": "药物",
"overlap": 0,
"start_pos": 388
},
{
"end_pos": 452,
"label_type": "药物",
"overlap": 0,
"start_pos": 449
},
{
"end_pos": 463,
"label_type": "药物",
"overlap": 0,
"start_pos": 461
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于2015.10.28在我院因“绝经2年后阴道不规则流血2月”行经腹广泛性子宫+两附件切除术+盆腔淋巴结清扫术，手术顺利，术后病理示：（38711.15）（宫颈）中低分化鳞状细胞癌，肿瘤切面积4.8×2.6CM，侵及宫颈全层及宫颈内口；阴道壁、右左宫旁组织未查见癌；右闭孔淋巴结4枚（0/4）、左闭孔淋巴结5枚（0/5）均未查见转移癌；右髂血管淋巴结9枚，其中8枚查见转移癌（8/9），左髂血管淋巴结7枚，其中1枚查见转移癌（1/7）；萎缩性子宫内膜，两侧输卵管大致正常，两侧卵巢白体。于2015.11.13行紫杉醇+顺铂化疗1周期，化疗过程中出现紫杉醇过敏，后于2015.12.09改为力朴素270MG+顺铂120MG化疗1周期，未诉明显不适。后为行进一步治疗转入我科，排除放化疗禁忌后，给予局部放疗计划，计划量DT=4500CGY/25F，同时顺铂40MG D1-3+力扑素270MG D1化疗1周期，过程顺利，无明显不适。后为行进一步诊治，就诊我院。排除化疗禁忌后于2016.2.16给予力扑素270MG D1+顺铂40MG D1-3化疗1周期，过程顺利，无明显不适。现为行上周期化疗再次收入我科。患者自下次出院以来，饮食睡眠可，大小便正常，体重无明显改变。 | |
[
{
"end_pos": 31,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 41,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 61,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 110,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 341,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 338
},
{
"end_pos": 350,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 353,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 351
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，2017年02月17日在全麻上行腹腔镜探查，根治性全胃切除术。，术后病理：（全胃和大网膜），切除： - 溃疡型低分化腺癌，LAUREN，分型：混合型； - 位于粘膜层； - 未见脉管癌栓； - （食管断端）、（十二指肠残端）未见癌； - 大网膜未见癌； - 淋巴结未见癌转移（第1组0/3、第2组0/2、第3组0/0、第4D组0/1、第4SA组0/0、第5组0/2、第7组0/3、第8A组0/1、第8P组0/2、第9组0/2、第11D组0/3、第12A组0/0、第6组0/3、第11P组0/4、第4SB组0/0）； - ，肿瘤病理分期：PT1AN0。，免疫组化结果显示:CD56(－),CGA(－),CK(+),KI-67(+40%),SYN(－)。术后恢复可。，术后基线：胸CT（-),腹盆，CT：盆腔少量积液，较前增多。2017-3-15 C125 76.84。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 55,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 66,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 83,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 149,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 137
},
{
"end_pos": 162,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 180
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 207
},
{
"end_pos": 224,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 245,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 408,
"label_type": "药物",
"overlap": 0,
"start_pos": 404
},
{
"end_pos": 425,
"label_type": "药物",
"overlap": 0,
"start_pos": 421
},
{
"end_pos": 458,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 457
},
{
"end_pos": 500,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 495
},
{
"end_pos": 525,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 524
},
{
"end_pos": 528,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 527
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前44天因“盲肠癌”于2016.05.30在全麻上行“腹腔镜上左半结肠根治性切除术”，，术中见：腹腔内无明显出血，无明显腹水，肿瘤位于盲肠，肿瘤侵犯左外侧腹壁，未形成梗阻，近端肠管无扩张，周围可见数个肿大淋巴结。术后病理（201618360），示：(左半结肠)，：结肠溃疡型管状腺癌II级，伴坏死，侵出外膜层；回肠末端淋巴组织增生。手术标本回肠切端、结肠切端及另送（近切端）、（远切端）均未见癌浸润。找到回肠周淋巴结1/5个、结肠周淋巴结3/10个，及另送(回结肠动脉根部)淋巴结2/2，见癌转移。，免疫组化：13号KI67（60%+），CK8（+++），CEA（+++），P53（-）；22号KI67（生发中心80%+，滤泡间区2%+），CD3（T细胞+++），CD20（B细胞+++），BCL-2（+++）。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。并于2016.06.23予“奥沙利铂150MGIVGTTD1+卡培他滨片1000MGPOBIDD1-14”方案化疗1周期，辅以制酸、保肝、止吐等预处理，化疗过程顺利，无明显不适。此次为化疗再次就诊我院，门诊拟“盲肠癌术后化疗”收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 29,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 24
},
{
"end_pos": 36,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 57,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 82,
"label_type": "手术",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 114,
"label_type": "手术",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 145
},
{
"end_pos": 163,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 214,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 209
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 254,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 242
},
{
"end_pos": 272,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 296,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 295
},
{
"end_pos": 299,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 362,
"label_type": "药物",
"overlap": 0,
"start_pos": 358
},
{
"end_pos": 378,
"label_type": "药物",
"overlap": 0,
"start_pos": 375
},
{
"end_pos": 450,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 445
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于入院前4个月因“反复血便6个月”住我院查腹部，CT:1、乙状结肠管壁不规则增厚，符合乙状结肠CA（浸润型）改变，侵犯浆膜层，伴周围少许淋巴结。2、阑尾切除术后改变。遂于2013.11.14全麻上“腹腔镜上乙状结肠癌根治术”，术顺，术后予预防感染、营养支持、补液等治疗。，术后病理：(乙状结肠)，:肠溃疡型管状腺癌II级，侵及深肌层，侵犯神经组织，手术标本下、上切端及另送(下切端)、(上切端)均未见癌浸润，找到肠周淋巴结17个，及另送(直肠下动脉旁染色淋巴结1)淋巴结1个，(直肠下动脉旁染色淋巴结2)淋巴结1个，(肠系膜上动脉)淋巴结2个均未见癌浸润。术后恢复可，进食半流质饮食无腹痛、腹胀等不适，创口愈合良好，于2013.12.23、2014.01.12、2014.02.05、2014.02.27予以“奥沙利铂200MGIVGTTD1+希罗达1500MGPOBIDD1-14”方案化疗，化疗期间辅以预防性制酸、止吐等治疗，化疗期间未见明显不适。今为第5次化疗就诊我院，门诊拟“结肠癌术后”收住入院，自患病以来患者精神、睡眠、饮食一般，大小便正常，体重无明显改变。 | |
[
{
"end_pos": 43,
"label_type": "手术",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 88,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 130,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 138,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 152,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 151
},
{
"end_pos": 261,
"label_type": "药物",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 264,
"label_type": "药物",
"overlap": 0,
"start_pos": 262
},
{
"end_pos": 279,
"label_type": "药物",
"overlap": 0,
"start_pos": 275
},
{
"end_pos": 284,
"label_type": "药物",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 352,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 351
},
{
"end_pos": 355,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 354
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4个月因“乙转结肠癌”于2014年01月09日行“腹腔镜上乙状结肠癌根治术”。术后病理（201400845），：1、（乙状结肠），：大肠溃疡型乳头状-管状腺癌II级，侵及浆膜，手术标本双切端及另送（下切端）、（上切端）均未见癌浸润。找到肿物周淋巴结9个，肠周淋巴结8个，均未见癌转移。2、（肠系膜上动脉根部）送检脉管、纤维及脂肪组织。，术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。于2014.02.04、2014.02.24、2014.03.17、2014.04.10、2014.4.30予“奥沙利铂(艾恒)200MG静滴D1+卡培他滨片(希罗达)1500MG口服BIDD1-14”方案化疗5周期，化疗过程顺利，辅以制酸、止吐等处理。此次为化疗再次入院。患者出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 8,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 80,
"label_type": "手术",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 106,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 112,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 107
},
{
"end_pos": 128,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 132,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 143,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 146
},
{
"end_pos": 157,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 174,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 167
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 177
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 218,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 206
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“，盆腔包块：卵巢癌？”于2013-12-30我可行肿瘤细胞减灭术（全子宫切除+两附件切除+盆腔淋巴结切除+腹主动脉淋巴结切除+大网膜切除+肠粘连松解术），术程顺利，术后恢复良好。，术后病理提示：两侧卵巢见低分化腺癌浸润，形态较符合高级别浆液性腺癌，子宫体后壁外膜层及肌层见腺癌浸润，宫颈管后壁外膜层见腺癌浸润，大网膜纤维组织中见低分化腺癌浸润，两侧输卵管、宫颈及盆腔淋巴结均未见癌。结合术后病理诊断为“卵巢低分化腺癌IIIC期”，今为术后辅助化疗收入院，患者近1月以来精神可，大小便无异常，体重无明显减轻。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 55,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 76,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 82,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 81
},
{
"end_pos": 109,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 112,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 116
},
{
"end_pos": 154,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 160,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 156
},
{
"end_pos": 176,
"label_type": "手术",
"overlap": 0,
"start_pos": 163
},
{
"end_pos": 187,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 193,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 191
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 195
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 219,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 230,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 237,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 266,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 257
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于3月余前因胰腺肿物于我科行胰十二指肠切除、联合胰腺体颈部切除、胃造瘘、空肠造瘘术”，，术后病理示:胰腺导管内乳头状粘连性肿瘤伴下皮重度不典型增生.术后予保肝、制酸、输白蛋白、对症等治疗。术后恢复可，予带T管、胃、空肠造瘘管、左腹腔引流管出院。2月余前T管管周出现明显渗液，呈浓稠状，，入院查下腹部CT示:腹腔积液.予行B超引导上腹腔穿刺置管引流后予抗感染、补液、保肝等处理后腹腔管、胃空肠造瘘管、T管均拔除后出院，现患者无腹痛、腹胀，无畏寒、发热，无眼黄、尿黄、皮肤黄等不适，今为进一步复查，来我院，门诊以胰十二指肠切除术后收入院。患者自发病以来饮食少，大小便无异常，体重无明显增减。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 66,
"label_type": "手术",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 145,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 161,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 227,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 245,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 344,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 352,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 350
},
{
"end_pos": 356,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 355
},
{
"end_pos": 359,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 358
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1年余因“食管中段癌（PT2N0M0）II期”就诊我院2013.08.12在全麻上行食管中段癌切除+食管-胃底弓下吻合术，，术中探查：胸腔无粘连，无淡黄色积液；肿物位于主动脉弓后，局部增厚约2.5CM，未累及外膜，食管旁多发淋巴结肿大。，术后病理示：（201324854）(食管)，：食管溃疡型鳞状细胞癌II级，侵及深肌层（1/2肌层），手术标本下上切端均未见癌浸润，找到食管周淋巴结3个及另送(中段食管旁）淋巴结11个，(胃右动脉旁）淋巴结14个，均未见癌转移，(贲门旁淋巴结）为血管、脂肪、纤维结缔组织及横纹肌组织。，免疫组化结果：KI67（50%），P53（+++），P170（-），GSTπ（+++），EGFR（+++）。现为术后复查再次就诊我院。下次出院至今患者无胸闷、憋气；无胸背痛；无腹痛、腹胀；无呕血、黑便；偶有返酸。饮食睡眠较好。大小便正常。体重无明显变化。 | |
[
{
"end_pos": 9,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 37,
"label_type": "手术",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 61,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 73,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 82,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 121,
"label_type": "药物",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 125,
"label_type": "药物",
"overlap": 0,
"start_pos": 122
},
{
"end_pos": 144,
"label_type": "药物",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 148,
"label_type": "药物",
"overlap": 0,
"start_pos": 145
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者因\"子宫肌瘤\"于2013年9月10日行全子宫切除术+右侧附件切除术，术后外院病理结果示子宫内膜样腺癌（中-低分化），浸润深肌层，累及宫颈管，诊断为子宫内膜癌。术后恢复可。2013-10-30、2013-11-22行TP方案化疗（多帕菲、伯尔定）2程。2013-12-12行“力朴素+伯尔定”化疗1程。现按主诊教授意见入院行上一程化疗。患者近期精神、睡眠、胃纳可，大小便无异常，体重未见明显减轻。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 95,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 243,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 240
},
{
"end_pos": 246,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 320,
"label_type": "药物",
"overlap": 0,
"start_pos": 316
},
{
"end_pos": 333,
"label_type": "药物",
"overlap": 0,
"start_pos": 329
},
{
"end_pos": 342,
"label_type": "药物",
"overlap": 0,
"start_pos": 338
},
{
"end_pos": 365,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 364
},
{
"end_pos": 399,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 398
},
{
"end_pos": 401,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 400
},
{
"end_pos": 434,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 427
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者约于6个月前因“乙状结肠癌”于2017-01-23在全麻上行“乙状结肠根治术”，手术过程顺利，术后患者恢复好，切口愈合好，按期拆线。术后病理( 201701617)，：乙状结肠粘液腺癌，浸润溃疡型，体积6.5*4*1.3CM，局部侵穿浆膜。双端切线及另送“近切线”、“远切线”未查见癌。呈一站（3/8个）、中间组（1/8个）淋巴结癌转移。，免疫组化染色示癌组织：SYN（-）、BRAF（-）、MLH1（+）、MSH2（+）、MSH6（+）、PMS2（+）。患者术后出现发热，尿培养+药敏(20170204)，: 铜绿假单胞菌，给予抗炎、退热等药物治疗后，症状逐渐缓解后出院。患者出院后规律至我院复查，给予6周期化疗，，方案为：奥沙利铂200MG D1，亚叶酸钙0.3G+氟尿嘧啶0.75G D2-D6，同时给与升白细胞、护肝、止吐、免疫增强治疗，患者副反应轻。 院外期间，患者无发热，无腹痛腹胀不适，大便通畅。现患者为行复查化疗来我科就诊，以“乙状结肠癌术后”收入院。 病人自下次出院以来，神志清，精神可，饮食可，大、小便正常，体重未见明显变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 39,
"label_type": "手术",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 99,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 135,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 180,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 269,
"label_type": "药物",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 282,
"label_type": "药物",
"overlap": 0,
"start_pos": 278
},
{
"end_pos": 296,
"label_type": "药物",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 334,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 330
},
{
"end_pos": 395,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 394
},
{
"end_pos": 398,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 397
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因患“胃癌”于2017-07-10日在全麻上行全胃切除术+空肠J字代胃术，手术顺利，术后给予抗炎、抑酸、营养支持及对症支持治疗，术后病理示术后病理（201715979），示：胃体腺癌（低分化），浸润溃疡型，体积2.5*1*1.3CM，侵达浆膜。双端切线及另送“食管切线”未查见癌。一组（7个）、三组（2个）、四组（4个）、五组（1个）及六组（2个）淋巴结未查见癌。，免疫组化染色示：CERBB-2（-）、SYN（-）、β-TUBULIN-III少数（+）、RRM1（-）、TOPOII部分（+）。术后给予化疗1疗程，，方案：奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1000MG D2-6 静滴，现患者为行复查化疗来我院就诊，门诊以“胃癌术后”收入院。自下次出院后，患者一般情况保持良好， 无乏力感，无发热，无恶心、呕吐，无反酸、嗳气，无明显进食不适，未现明显 腹痛、腹胀；大小便情况良好。目前患者精神及情绪状态可，食欲、饮食好，夜间睡眠可，大小便正常，近期无明显体重变化。 | |
[
{
"end_pos": 21,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 35,
"label_type": "手术",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 56,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 87,
"label_type": "手术",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 126,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 199,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 193
},
{
"end_pos": 242,
"label_type": "药物",
"overlap": 0,
"start_pos": 238
},
{
"end_pos": 245,
"label_type": "药物",
"overlap": 0,
"start_pos": 243
},
{
"end_pos": 249,
"label_type": "药物",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 269,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 307,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 303
},
{
"end_pos": 310,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 307
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者1年余前（2014-9-30）因“胃癌”于我院行胃癌根治术（毕I），术后给予消炎营养支持治疗，患者出现肠梗阻症状，于2014-10-15在全麻上行肠粘连松解术+空肠造瘘术，术后给予消炎、营养支持治疗，病情好转后出院。术中常规病理示：（胃）中分化腺癌，溃疡型，肿物切面积4.5*1CM，侵达浆膜脂肪组织，双端切缘及吻合器切缘未查见癌。小弯侧淋巴结22枚，其中2枚（2/22）查见转移；大弯侧淋巴结12枚，其中4枚（4/12）查见转移。另送网膜组织内未查见癌。后患者再次入院行奥沙利铂+CF+替加氟方案化疗8个周期，耐受良好。后患者反复腹痛，给予对症后症状均可缓解。现患者为进一步诊疗，再次来我院，门诊以“胃癌术后肠粘连”收入院。自发病以来，患者神志清，精神可，睡眠尚可，昨日排便一次，小便无明显异常，体重较下次入院无明显改变。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 32,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 53,
"label_type": "手术",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 62,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 65,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 85,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 129,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 154,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 232,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 227
},
{
"end_pos": 243,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 238
},
{
"end_pos": 254,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 265,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 275,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 270
},
{
"end_pos": 293,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 313,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 302
},
{
"end_pos": 402,
"label_type": "药物",
"overlap": 0,
"start_pos": 398
},
{
"end_pos": 418,
"label_type": "药物",
"overlap": 0,
"start_pos": 415
},
{
"end_pos": 443,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 442
},
{
"end_pos": 446,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 445
},
{
"end_pos": 482,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 477
},
{
"end_pos": 506,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 505
},
{
"end_pos": 509,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 508
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院3月余前我院诊断为贲门癌，于2015.11.06在气管插管全麻上行“腹腔镜辅助上根治性全胃切除术”，，术中见：腹腔内无腹水，腹腔内未见明显转移结节，肿瘤位于贲门，大小约5.0×5.0CM，呈浸润溃疡型，侵及浆膜层，周围有肿大淋巴结.术中诊断“贲门癌”。，术后病理示：食管胃交界处溃疡型中－低分化腺癌,侵犯浆膜层，侵犯脉管及神经组织，间质见多量淋巴细胞浸润。手术标本下切端粘膜上层可见脉管癌栓，标本上切端均未见癌浸润。找到贲门周淋巴结9/20个，小弯淋巴结0/29个，大弯淋巴结0/8个，幽门下淋巴结0/3个，幽门上淋巴结0/4个，网膜淋巴结0/1个及另送（胃右动脉根部）淋巴结1/9个见癌转移。（胃右动脉根部）淋巴结见多发下皮样结节，呈肉芽肿性炎改变。术后给予对症、营养支持等处理，恢复良好，切口愈合为II/甲。术后于2015.12.5、2015.12.27、2016.01.23予以“伊立替康240MGIVGTTD1+替吉奥60MGPOBIDD1-D14”方案化疗，辅以保胃、保肝、增强免疫、营养补液治疗。今为术后4次化疗，再次入院，门诊拟“贲门癌术后化疗”收入住院，自下次出院以来饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 83,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 211,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 216,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 214
},
{
"end_pos": 224,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 219
},
{
"end_pos": 250,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 249
},
{
"end_pos": 283,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 285,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 284
},
{
"end_pos": 311,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 309
},
{
"end_pos": 328,
"label_type": "手术",
"overlap": 0,
"start_pos": 318
},
{
"end_pos": 366,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 361
},
{
"end_pos": 373,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 367
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“直肠癌”于2015-06-16在我院在全麻上行根治性DIXON手术，手术过程顺利，术后患者恢复好，切口愈合好，按期拆线。，术后病理：（直肠）腺癌（中度分化），隆起型，体积8.5*7*1.5CM，侵达深肌层，底部切除面 未查见癌。 双端切线及另送“近切线”、“远切线”未查见癌。 一站（5个）、中央组（11个）、中间组（1个）淋巴结未查见癌。 ，免疫组化染色示：TS少量（+）、SYN（-）。后患者出现发热及左下腹痛，行CT检查示胆总管结石并以下水平胆系扩张，请肝胆外科会诊后给予抗生素及保肝治疗，患者症状明显好转。 院外期间患者一般情况好，无恶心，无腹痛腹胀不适，2015年9月21日门诊行结肠镜检查发现结肠多发息肉，并行内镜上结肠息肉电切术，术后恢复好，现患者为行复查再次来院就诊，为行进一步治疗，门诊以“直肠癌术后、结肠多发息肉”收入院。 近期患者精神可，饮食可，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 19,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 63,
"label_type": "手术",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 110,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 162,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 157
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 193,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 184
},
{
"end_pos": 210,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 307,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 301
},
{
"end_pos": 323,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 322
},
{
"end_pos": 501,
"label_type": "药物",
"overlap": 0,
"start_pos": 497
},
{
"end_pos": 504,
"label_type": "药物",
"overlap": 0,
"start_pos": 502
},
{
"end_pos": 521,
"label_type": "药物",
"overlap": 0,
"start_pos": 518
},
{
"end_pos": 588,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 582
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2个月在我院诊为“降结肠癌”，并于2014.04.28在全麻上行“腹腔镜辅助上根治性右半结肠切除术+小肠肿物切除术”，术顺，术后病理（201412664），：（右半结肠），：1.肠隆起型绒毛状-管状腺癌II级，癌组织侵犯脉管组织，侵及浅肌层。手术标本双切端及另送（下切端）、（上切端）均未见癌浸润；找到肠周淋巴结23个，均未见癌转移。肠周见癌结节1个。2.肠绒毛状-管状腺瘤，伴腺下皮低级别下皮内瘤变。（小肠），：送检组织镜上为梭形细胞增生结节（最大径0.5CM），细胞核呈短梭形，可见核仁，胞浆嗜碱性，排列呈束状，核分裂像少见（<2个/50HPF），结合免疫组化结果，考虑危险度低的胃肠道间质瘤，因送检组织均为肿瘤组织，未见肠粘膜，无法判断切缘情况，请结合临床诊断。建议随访。，免疫组化结果：CK(PAN)（-），CD117（+++），CD34（++），DOG1（+++），DESMIN（-），H-CALDESMON（-），ACTIN(SM)（-），S100（个别细胞阳性），NF(PAN)（-），CD57（-），KI67（2%阳性）。术后予营养支持治疗，恢复良好。术后按“奥沙利铂(齐沙)150MGIVGTTD1+希罗达1000.00MGPOBIDD2-15”方案化疗，于2014-05-28行第1周期化疗。今入院行术后第2周期化疗，门诊拟“降结肠癌术后化疗”收住入院。自术后出院以来，精神、睡眠、食欲尚可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 49,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 85,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 130,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 125
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 332,
"label_type": "药物",
"overlap": 0,
"start_pos": 328
},
{
"end_pos": 349,
"label_type": "药物",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 382,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 381
},
{
"end_pos": 425,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 418
},
{
"end_pos": 449,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 448
},
{
"end_pos": 452,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 451
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊为乙状结肠癌，于2015-05-03在全麻上行腹腔镜上乙状结肠根治性切除术，术后病理（201614352），示：“乙状结肠浸润性管状腺癌I-II级，侵及浆膜上层。手术标本下、上切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结10个，及另送的（直肠下动脉根部）淋巴结3个，均未见癌转移。，免疫组化：KI-67（20%+），CK7（+），CK20（+++），VILLIN（++++），CDX2（+++），β-CATENIN（膜+++）。该病例未检测到KRAS基因12、13号密码子热点突变。，病理：该病例未检测到BRAF基因V600E突变”，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。2016.06.03予“奥沙利铂200MGIVGTTD1+卡培他滨1500MGPOBIDD2-14”方案化疗1个疗程，辅以止吐、保肝、制酸、增强免疫等治疗，无明显化疗毒副反应。此次为行上一周期化疗，门诊拟乙状结肠癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 47,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 58,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 56
},
{
"end_pos": 63,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 62
},
{
"end_pos": 67,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 82,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 80
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 97,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 165,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 183,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 232,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 262,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 275,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 267
},
{
"end_pos": 288,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 280
},
{
"end_pos": 319,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 300
},
{
"end_pos": 335,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 339,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 343,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 414,
"label_type": "药物",
"overlap": 0,
"start_pos": 410
},
{
"end_pos": 467,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 466
},
{
"end_pos": 470,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 469
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前25天因胃体癌于2015年11月24日在我院全麻上行“腹腔镜辅助上根治性全胃切除术”，，术中探查见：腹腔内无明显腹水，盆腔、腹壁、大网膜无转移结节，肝脏质地大小正常，胆囊无肿大。胃体病灶不能探及，周围无明显肿大淋巴结，手术顺利，术后予抗感染、营养支持、免疫等治疗，术后恢复良好，术后病理（201541588），：（全胃)，:胃窦小弯侧溃疡型管状腺癌II级，侵犯肌层。手术标本下、上切端及另送（下切端）均未见癌浸润。找到贲门周淋巴结0/7个，幽门上淋巴结0/13个，及另送(第1组）淋巴结0/1个、（第7组）淋巴结1/7个、（第8组）淋巴结2/9个、（第9组）淋巴结0/2个，见癌转移。另送（第11组淋巴结）、（第12组淋巴结）镜上为纤维、血管、脂肪组织。小弯侧、幽门下、大弯侧脂肪组织未找见淋巴结；，免疫组化：肿瘤细胞示KI67（20％阳性），P53（-），P170（++），GSTπ（-），EGFR（-），5-FU（+），HER-2（+），CK(L)（++）。此次为术后第1周期化疗再次入院。患者出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 66,
"label_type": "手术",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 104,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 158,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 162,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 161
},
{
"end_pos": 167,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 228,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 223
},
{
"end_pos": 254,
"label_type": "药物",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 257,
"label_type": "药物",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 272,
"label_type": "药物",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 277,
"label_type": "药物",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 307,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 306
},
{
"end_pos": 310,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 309
},
{
"end_pos": 355,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 350
},
{
"end_pos": 378,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 377
},
{
"end_pos": 381,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 380
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2月余于我院诊为“直肠癌”，于2015-10-12在全麻上行腹腔镜上直肠根治术（DIXON手术）中转开腹+膀胱病损修补术，，术中见：腹腔内无明显出血，肿瘤位于直乙交界处，与膀胱分界不清，形成肠梗阻，近端稍扩张，周围见数个明显肿大淋巴结。，术后病理：（201541031）（直肠），：肠外生型管状腺癌II级，侵犯肠壁全层及肠周脂肪组织，间质见多量急慢性炎症细胞及组织细胞浸润。手术标本双切端及另送(下切端)、(上切端)均未见癌浸润。找到肠周淋巴结68个未见癌转移。于2015.12.18予“奥沙利铂(艾恒)200MG静滴D1+卡培他滨片(希罗达)1500MG口服BIDD1-14方案”化疗，辅予止吐、保胃、护肝等相关治疗。化疗过程顺利，无化疗副反应。此次为第2次化疗，再次就诊我院，门诊拟“直肠癌术后化疗”收入我科。自下次出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 76,
"label_type": "手术",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 109,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 126,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 153,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 140
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 183,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 218,
"label_type": "药物",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 228,
"label_type": "药物",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 275,
"label_type": "药物",
"overlap": 0,
"start_pos": 273
},
{
"end_pos": 285,
"label_type": "药物",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 316,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 315
},
{
"end_pos": 319,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 318
},
{
"end_pos": 357,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 352
},
{
"end_pos": 374,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 373
},
{
"end_pos": 380,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 379
},
{
"end_pos": 381,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 380
},
{
"end_pos": 385,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 384
},
{
"end_pos": 388,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 387
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者8个月前因“进行性吞咽困难1个月”就诊于我院，完善术前准备后，于2013-10-08行“胸段段食管食管切除+食管-胃左胸顶吻合术+左侧第5肋骨固定术”，术顺，术后恢复良好后出院。术后病理示：胸段食管多中心鳞状下皮癌，其一为溃疡性鳞状细胞癌I-II级，侵犯神经，侵出外膜，其二为浸润型鳞状细胞癌I-II级，侵犯神经及齿状线。找到贲门淋巴结1/7，左喉返神经旁淋巴结1/3，见癌转移。于2013.12.01、2013.12.26按“洛铂50MGD1+多帕菲120MGIVGTT”方案化疗2个周期，并于2014.01.19、2014.02.13按“洛铂50MGD1+安素泰180MGD2IVGTT”方案化疗第3、4周期，辅以制酸、保胃、保肝、止吐等治疗，化疗过程顺利，现为化疗4周期后复查就诊我院，门诊拟“食管癌术后化疗后”收住入院。下次出院至今无胸闷、憋气、胸背痛，无腹痛、腹胀，无呕血、黑便。精神、睡眠、饮食较好，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 23,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 47,
"label_type": "手术",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 62,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 76,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 79,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 100,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 129,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 151,
"label_type": "药物",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 155,
"label_type": "药物",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 165,
"label_type": "药物",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 169,
"label_type": "药物",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 199,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 198
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者2008.2.1因“大便性状改变，发现结肠肿块10天”入我院全科，2.5行乙状结肠癌根治术（应用吻合器），术中探查：腹腔及其他脏器未及异常，乙状结肠近直肠处可及4×4CM肿块，术中病理“溃疡性腺癌，分化II－III级，侵及全层，切缘未见癌累及，肠旁淋巴结19枚，均未及癌转移”。分别1.28（乐沙定，君瑞清），2.23（乐沙定，替加氟）行介入化疗。今为再次行介入化疗入院。病程中，患者精神可，胃纳差，睡眠可，双便正常。 | |
[
{
"end_pos": 19,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 52,
"label_type": "手术",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 77,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 81,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 97,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 159,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 174,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 230,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 224
},
{
"end_pos": 248,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 236
},
{
"end_pos": 263,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 251
},
{
"end_pos": 276,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 327,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 326
},
{
"end_pos": 330,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 329
},
{
"end_pos": 334,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 337,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 336
},
{
"end_pos": 340,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 339
},
{
"end_pos": 370,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 363
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊断为结肠肝曲癌，于2014-10-20在全麻上行腹腔镜上扩大根治性左半结肠切除术，，术中见：腹腔内无明显出血，无明显粘连，无明显腹水，肝脏无明显转移结节，肿瘤位于结肠肝曲，大小约5*3CM，侵出浆膜层，未明显侵及十二指肠，周围可及多发肿大淋巴结。术后病理（病理号201435395）示（左半结肠），：大肠隆起型管状腺癌II级，侵及浆膜，侵犯神经，手术标本双切端及另送（近切端）、（远切端）均未见癌浸润。找到回肠周淋巴结1个，结肠周淋巴结50个，另送（回结肠动脉根部）淋巴结5个，（结肠中动脉根部）淋巴结5个均未见癌转移。另见阑尾组织，术后给予对症、营养支持等治疗，恢复良好，伤口愈合II/甲，出院后无发热、畏冷，无咳嗽、咳痰，无胸闷、心悸，无腹痛、腹胀、腹泻等不适，今为行术后第1次化疗就诊我院，门诊拟结肠肝曲癌术后收入院。下次出院以来，精神、睡眠、饮食可，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 21,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 24,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 27,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 34,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 50,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 84,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 95,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 94
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 113,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 111
},
{
"end_pos": 141,
"label_type": "手术",
"overlap": 0,
"start_pos": 131
},
{
"end_pos": 166,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 158
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 247,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 266,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 264
},
{
"end_pos": 361,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 327
},
{
"end_pos": 451,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 446
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2月前于我院在全麻上行手术，探查腹腔内无腹水，腹膜无转移，肝脏未触及转移结节，肿瘤位于结肠肝曲，约5×4×4CM，已侵出浆膜，侵犯十二指肠和胰头，并造成肿瘤与盲肠之间闭袢性梗阻，梗阻肠腔明显扩张，肠腔内大量稀薄粪便，结肠系膜未见明显肿大淋巴结，探查后决定行姑息性左半结肠切除术。手术过程顺利。，术后病理结果示：（左半结肠）腺癌（中度分化），结合免疫组化考虑来自结肠，部分细胞伴神经内分泌分化。浸润溃疡型，体积4.5*3.5*1.2CM，侵穿浆膜及纤维膜。，术后病理结果示：（左半结肠）腺癌（中度分化），结合免疫组化考虑来自结肠，部分细胞伴神经内分泌分化。浸润溃疡型，体积4.5*3.5*1.2CM，侵穿浆膜及纤维膜。 双端切线及底部切除面未查见癌。 肠壁一站(8个)、二站(4个)、三站(3个)、中间组(5个)淋巴结未查见癌。 ，免疫组化染色示：CK7(-)、CK20(+)、VILLIN(+)、CDX-2(+)、TS部分(+)、 SYN（少数细胞阳性）。现患者为行进一步诊治，门诊以“结肠癌术后”收入我科。患者术后精神、饮食可，小便正常，大便排便费力，体重无明显变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 79,
"label_type": "手术",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 93,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 100,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 112,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 261,
"label_type": "药物",
"overlap": 0,
"start_pos": 258
},
{
"end_pos": 269,
"label_type": "药物",
"overlap": 0,
"start_pos": 267
},
{
"end_pos": 303,
"label_type": "药物",
"overlap": 0,
"start_pos": 300
},
{
"end_pos": 311,
"label_type": "药物",
"overlap": 0,
"start_pos": 309
},
{
"end_pos": 367,
"label_type": "药物",
"overlap": 0,
"start_pos": 364
},
{
"end_pos": 379,
"label_type": "药物",
"overlap": 0,
"start_pos": 377
},
{
"end_pos": 395,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 393
},
{
"end_pos": 444,
"label_type": "药物",
"overlap": 0,
"start_pos": 441
},
{
"end_pos": 452,
"label_type": "药物",
"overlap": 0,
"start_pos": 450
},
{
"end_pos": 469,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 468
},
{
"end_pos": 477,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 476
},
{
"end_pos": 478,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 477
},
{
"end_pos": 498,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 493
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“宫颈癌”于2015-09-02在我院于全麻上行腹腔镜上盆腔淋巴结清扫+腹主动脉旁淋巴结取样+广泛子宫+两侧输卵管切除术+左侧卵巢切除+右侧卵巢悬吊术。，术后病理检查示：宫颈腺癌，符合中肾管癌，侵犯宫颈壁全层及宫颈管内口。右盆腔淋巴结12枚，其中一枚查见转移癌（31622.15)。，免疫组化：ER(-) PR(-) CR(-) CK(-) P16(-) NAPSINA(-)PAX-8个别腺体弱阳性，P53(-) CEA(+) WT-1(-)KI-67阳性率50%。术后一般情况可，2015-09-14给予紫杉醇240MG+顺铂110MG化疗，化疗过程顺利，副反应不重。2015-10-9予紫杉醇240MG+顺铂110MG方案化疗，予心电监护，水极化，化疗过程顺利，无明显化疗反应。2015-11-9 在我院放疗二科予紫杉醇240MG D1 +顺铂40MG D1-3方案化疗，盆腔适形放疗中，放化疗过程顺利，情况好转出院。于2015-12-25日、2016-1-17日给予紫杉醇240MG+顺铂110MG药物化疗2次。现患者无腹痛，无发热，无腰骶疼痛。为求第6次化疗，门诊以“宫颈癌术后化疗”收入院。患者一般情况可，睡眠饮食可，大小便无明显异常，体重无明显减轻。 | |
[
{
"end_pos": 23,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 53,
"label_type": "手术",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 61,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 113,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 122
},
{
"end_pos": 135,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 185,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 244,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 267,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 256
},
{
"end_pos": 276,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 283,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 295,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 305,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 316,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 308
},
{
"end_pos": 326,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 320
},
{
"end_pos": 352,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 390,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 385
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2015年11月26日因“宫颈癌IAI”在全麻上行腹腔镜上广泛子宫+两附件切除术+盆腔淋巴结清扫术。，术中见：子宫表面光滑，正常大小，两侧输卵管、卵巢均未见明显异常。两侧骶、主韧带无明显增厚。两侧盆腔未见明显肿大淋巴结。窥器扩开宫颈口，宫颈后唇可见活检创面，阴道壁粘膜光滑，无异常，术毕安返病房。，术后常规病理回示：（942790.15）（子宫）低分化鳞状细胞癌，4处癌灶，，切面积分别是：0.8*0.3CM、0.4*0.2CM、0.3*0.2CM、0.2*0.1CM，侵及宫颈管深度小于1/3，并查见鳞状下皮高级别下皮内瘤变累及腺体。右、左宫宫旁组织及阴道断端未查见癌。萎缩的子宫内膜。（两侧）输卵管组织。（两侧卵巢）白体。另送检右盆腔淋巴结4枚，均未查见转移癌（0/4)，另送检“左盆腔淋巴结”为脂肪结缔组织，未查见癌。。今为术后第1次化疗就诊我院，门诊以“宫颈癌术后化疗”收入院，患者自发病以来，饮食睡眠可，体重无明显变化。 | |
[
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 58,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 171,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 212,
"label_type": "手术",
"overlap": 0,
"start_pos": 194
},
{
"end_pos": 221,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 220
},
{
"end_pos": 235,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 231
},
{
"end_pos": 246,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 255,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 288,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 284
},
{
"end_pos": 295,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 291
},
{
"end_pos": 479,
"label_type": "药物",
"overlap": 0,
"start_pos": 477
},
{
"end_pos": 496,
"label_type": "药物",
"overlap": 0,
"start_pos": 492
},
{
"end_pos": 557,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 556
},
{
"end_pos": 560,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 559
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者6个月前（2014-5）无明显诱因出现排便习惯改变，大便2-4次/日，呈稀糊状，伴里急后重感，无脓血，无腹痛腹胀，无恶心呕吐，无发热，自诉口服中药（具体不详）效果不明显。遂就诊于我院消化内科，2014年7月9日，行肠镜检查示：，直肠：肛缘至距肛缘约7CM见约环2/3管腔不规则隆起病变，表面糜烂结节状。，诊断意见：直肠CARCINOMA。2014年7月16日于我院胃肠外科在全麻上行腹会阴直肠癌根治术（MILES手术），术中见肿瘤位于腹膜返折上方，巨大充满小骨盆腔，，术后病理示：距肛门侧切缘4CM处，肠粘膜面见8*7*2.5CM灰白溃疡型肿物，，诊断意见：A(直肠肿瘤)，:黏液腺癌(中低分化)，侵及外膜；L251(14/14)、L252(3/8)，：淋巴结转移癌；L253(0/1)，：淋巴结淋巴组织增生（，病理号：Z0480550）。，免疫组化：，A2：C-ERBB-2(1+) D2-40(-) CEA(+) CK20(+) CK7(-) KI-67(约50%+) CD34(-)。术后恢复可，于我科行XELOX方案化疗3周期，，具体用药：艾恒 200MG D1 静点，希罗达 1500MG 日二次口服。末次化疗后出现I°粒细胞上降，未治疗。现为行进一步治疗收入我科。患者目前一般状况可，无发热，无腹痛、腹泻及便血，饮食睡眠可，二便正常，周身无疼痛，病来体重无明显减轻，ECOG评分1分。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 30,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 84,
"label_type": "手术",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 107,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 111,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 136,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 128
},
{
"end_pos": 255,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。2年前，患者因“反复腹胀1年”入我院，考虑“胃底贲门恶性肿瘤可能”，2014-09-19在我院于全麻上行“剖腹探查、根治性全胃切除术、食管-空肠ROUX-EN-Y吻合术”，手术顺利，术后病理诊断示“（胃）中分化腺癌，侵及肠壁全层至浆膜外，双切端未见癌累及，胃大、小弯淋巴结未见癌转移（分别为0/5、0/9），网膜未见癌累及”。术后积极予以抗感染、营养支持、对症和支持治疗，患者好转出院。术后已行6次全身静脉化疗（FOLFOX方案）。现嘱医嘱，为例行术后复查收入我科。\U0004 患者起病以来，精神尚可，胃纳可，睡眠可，大小便正常，体重未见明显改变。 | |
[
{
"end_pos": 15,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 34,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 99,
"label_type": "手术",
"overlap": 0,
"start_pos": 51
},
{
"end_pos": 114,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 107
},
{
"end_pos": 219,
"label_type": "药物",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 231,
"label_type": "药物",
"overlap": 0,
"start_pos": 228
},
{
"end_pos": 265,
"label_type": "药物",
"overlap": 0,
"start_pos": 262
},
{
"end_pos": 276,
"label_type": "药物",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 310,
"label_type": "药物",
"overlap": 0,
"start_pos": 307
},
{
"end_pos": 321,
"label_type": "药物",
"overlap": 0,
"start_pos": 319
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者2016年8月因“发现上腹包块4个月”就诊我院，考虑卵巢恶性肿瘤，于2016-09-13于全麻上行肿瘤细胞减灭术（I型全子宫切除+两侧附件切除+大网膜切除+盆腔及腹主动脉旁淋巴结清扫+肠修补术），术中冰冻提示为高级别浆液性癌，手术为满意减灭术。因患者术前贫血，术中输注红细胞400ML及新鲜冰冻血浆400ML，无明显输血反应，手术过程顺利，术后予心电监护、吸氧、抗炎、补液等对症支持治疗。并于2016-09-20行TC方案（进口紫杉醇210MG D1，伯尔定550MG D1）化疗第一程、2016-10-12行TC方案（紫杉醇210MG D1+卡铂700MG D1）化疗第二程、2016-11-07行TC方案（紫杉醇210MG D1+卡铂700MG D1）化疗第三程，现为行上一程化疗入院。患者近期精神、睡眠稍差，食欲欠佳，二便如常，体重近期无明显改变。既往化疗及肿瘤标志物情况：。 | |
[
{
"end_pos": 10,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 1
},
{
"end_pos": 50,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 240,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 402,
"label_type": "药物",
"overlap": 0,
"start_pos": 399
},
{
"end_pos": 414,
"label_type": "药物",
"overlap": 0,
"start_pos": 411
},
{
"end_pos": 449,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 448
},
{
"end_pos": 450,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 449
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，根治性全胃切除术后2月余复查。，术后病理：胃体小弯侧溃疡型低分化腺癌（LAUREN，分型：弥漫型），大小5×3.5CM；侵至浆膜层，见神经侵犯，免疫组化CD34(+),D2-40(+)示脉管癌栓；食道残端及十二指肠残端均未见癌；淋巴结见癌转移【共44枚，21，枚转移：第1组0/5、第2组0/0、第3组8/13、第4SA组0/2、第4SB组0/0、第4D组5/7、第5组1/1、第6组5/5、（第7、9组）0/6、第8组1/1、第11P组0/1、12A组0/2、 14V1/1】；，肿瘤病理学分期：PT4N3B。，免疫组化结果显示:CD34(+),CD44(+),CMET(+),D2-40(+),EGFR(+),HER2(－),KI-67(+25～50%),P170(+),P27(+25～50%),P53(+25～50%),TOPOII(+＜25%)。术后化疗1周期SOX（2013-8-8，乐沙定200MG D1，爱斯万 60MG BID1-14，Q3WKS），骨髓毒性II度，升白治疗，胃肠道反应0度，外周神经毒性I度。 | |
[
{
"end_pos": 22,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 55,
"label_type": "手术",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 63,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 84,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 100,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 192,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 176
},
{
"end_pos": 200,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 224,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 229,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 227
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 271,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 292,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 280
},
{
"end_pos": 310,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 324,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 322
},
{
"end_pos": 448,
"label_type": "药物",
"overlap": 0,
"start_pos": 444
},
{
"end_pos": 461,
"label_type": "药物",
"overlap": 0,
"start_pos": 458
},
{
"end_pos": 538,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 528
},
{
"end_pos": 562,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 561
},
{
"end_pos": 565,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 564
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余于我院诊为结肠肝曲管状腺癌，于2014-10-20在全麻上行腹腔镜上扩大根治性左半结肠癌切除，，术中见：腹腔内无明显出血，无明显粘连，无明显腹水，肝脏无明显转移结节，肿瘤位于结肠肝曲，大小约5*5CM，侵出浆膜层，未明显侵及十二指肠，周围可及多发肿大淋巴结。术后病理（病理号201435397、201433427），：（左半结肠），：大肠溃疡型管状腺癌II-III级，部分为粘液腺癌，侵出浆膜，侵犯神经，脉管内见癌栓，手术标本回肠切端、结肠切端及另送（近切端）、（远切端）均未见癌浸润。找到回肠周淋巴结0/5个，结肠周淋巴结7/27个，及另送（结肠中动脉根部）淋巴结3/11个，（回结肠动脉根部）淋巴结0/6个，见癌转移。另见阑尾组织。该病例未检测到KRAS基因12、13号密码子热点突变、BRAF基因V600E突变。，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。于2014-11-29、2014-12-20、2015-01-10、2015-02-03予“奥沙利铂150MG静滴D1+希罗达1000MG口服D2-15”行第1、2、3、4次化疗方案，化疗过程顺利，无明显化疗副作用。此次为拟行第5次化疗方案再次就诊我院，门诊拟结肠肝曲管状腺癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 29,
"label_type": "手术",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 66,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 70,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 150,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 146
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于1年前因左肝原发性肝癌于我院行左半肝切除术+胆囊切除术,术顺,术后病理(201237164)示:左半肝肝脏原发性巨块型中分化肝癌,侵及肝被膜,脉管内见癌栓,周边组织呈空泡性及脂肪性变.术后恢复可。无腹胀、腹痛。无恶心、呕吐，无发热、寒战及黄疸。无畏冷、寒战、发热。现患者返院复查，门诊拟“肝癌术后”收住入院，自发病以来，患者食欲尚可，精神可，体重无明显上降，大、小便正常。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 43,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 52,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 70,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 231,
"label_type": "药物",
"overlap": 0,
"start_pos": 228
},
{
"end_pos": 242,
"label_type": "药物",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 278,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 311,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 299
},
{
"end_pos": 333,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 332
},
{
"end_pos": 336,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 335
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前4月余于我院诊为直肠癌，于2014-07-07在全麻上行腹腔镜上直肠癌根治术。术后病理示（直肠）：大肠隆起型管状-绒毛状腺癌II级，侵及外膜，侵犯神经，脉管内见癌栓，手术标本双切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结5/16个见癌转移。未检测到BRAF基因V600E突变。检测到KRAS基因12号密码子GLY12ASP和13号密码子GLY13ASP突变。，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。术后于我院以乐沙定200MGD1+希罗达1500MGD1-D14方案行4周期化疗,化疗过程顺利，化疗期间复查CT，效果良好。此次为化疗再次就诊我院，门诊拟直肠管状-绒毛状腺癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 23,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 57,
"label_type": "手术",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 98,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 192,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 184
},
{
"end_pos": 272,
"label_type": "药物",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 355,
"label_type": "药物",
"overlap": 0,
"start_pos": 351
},
{
"end_pos": 371,
"label_type": "药物",
"overlap": 0,
"start_pos": 368
},
{
"end_pos": 432,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 431
},
{
"end_pos": 435,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 434
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于2个月余前入院，诊断为直肠隆起型管状腺癌，于2014.01.16在我科行“腹腔镜上直肠癌根治术（DIXON）”。术后病理示（201401611），：(直肠)，：肠隆起型绒毛状-管状腺癌II级，侵犯脉管组织，脉管内见癌栓，侵及深肌层（>1/2肌层），手术标本双切端、环周切缘及另送(下切端)、(上切端)均未见癌浸润。找到肠周淋巴结2/18个，见癌转移。另送(肠系膜上动脉根部)镜上为脂肪、脉管及纤维结缔组织。，免疫组化结果：KI67（80%阳性），P53（+++），P170（++），GSTπ（个别细胞阳性），EGFR（-），5-FU（-），MLH1（+++），MSH6（个别细胞阳性），MGMT（++）。术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。并于2014.02.16开始予“奥沙利铂150MGIVGTTD1+希罗达1000MGPOBIDD2-15”方案行术后第1周期化疗，患者耐受良好，此次为第2次化疗再次入院。出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 7
},
{
"end_pos": 14,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 47,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 65,
"label_type": "手术",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 71,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 83,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 176,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 150
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，外院肠镜示：乙状结肠距肛门20CM可见环周样结节状粘膜不规则隆起。，病理：乙状结肠高分化腺癌。2017-8-22行乙状结肠癌手术，（直肠下段），切除：- 中分化腺癌，伴钙化，最大径4.5CM；- 可见脉管癌栓及神经侵犯；- 癌组织侵达浆膜上，浆膜上另见癌结节；- （近端）及（远端）切缘未见癌；- 淋巴结可见癌转移（肠周1/13，直肠下动脉旁0/1），未侵犯淋巴结被膜外；- ，肿瘤病理分期：PT3N1A。，免疫组化结果显示:BRAF(－),CMET(2+),EGFR(3+),HER2(1+),KI-67(70%),MLH1(+),MSH2(+),MSH6(+),PMS2(+)。 | |
[
{
"end_pos": 19,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 57,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 154,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 236,
"label_type": "药物",
"overlap": 0,
"start_pos": 232
},
{
"end_pos": 297,
"label_type": "药物",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 301,
"label_type": "药物",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 318,
"label_type": "药物",
"overlap": 0,
"start_pos": 315
},
{
"end_pos": 344,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 382,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 377
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前3月余于我院诊断为“直肠癌”，于2014-10-09行“腹腔镜上直肠癌根治术”，术顺，术后病理示（直肠），：肠溃疡型管状腺癌II级，癌组织侵犯脉管及神经组织，侵及外膜层。手术标本双切端、环周切缘及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结2/9个见癌转移。另送(肠系膜上动脉根部淋巴结)镜上为脂肪、脉管、神经及纤维结缔组织。，免疫组化染色结果：KI67（50%阳性），P53（+++），P170（+++），GSTπ（+），EGFR（++），5-FU（+），MLH1（+++），MSH-6（+++），MGMT（-）。于2014.11.19、2014.12.24予按奥沙利铂(乐沙定)200MGIVGTTD1+希罗达1000MGPOBIDD1-D14方案化疗，辅以保肝、止吐、制酸等对症处理，化疗过程顺利，此次为行第3次化疗，门诊拟“直肠癌术后化疗”收入我科。自入院以来，精神、睡眠、饮食良好，体力情况良好，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 51,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 72,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 82,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 103,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 148,
"label_type": "手术",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 164,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 172,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 206,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 204
},
{
"end_pos": 211,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 209
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 214
},
{
"end_pos": 231,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 261,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 310,
"label_type": "药物",
"overlap": 0,
"start_pos": 306
},
{
"end_pos": 324,
"label_type": "药物",
"overlap": 0,
"start_pos": 319
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 333
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2016.1.28因左下腹疼痛4天入我院普外科。当时无恶心、呕吐，无反酸、嗳气，无呕血，腹部CT示结肠肝曲占位，考虑结肠癌并腹腔淋巴结转移，腹部B超示左侧腹部包块，考虑占位性病变，肠系膜及腹膜后淋巴结肿大。入院后给予完善各项检查，于2016-1-30在全麻上行腹腔镜扩大根治性左半结肠切除术，，术后病理：（结肠）中分化腺癌，部分为粘液腺癌（后者约占60%），溃疡型，肿瘤切面积9*2.5CM，侵透浆膜，回肠切缘、结肠切缘、阑尾及网膜组织未查见癌，肠周淋巴结36枚，其中1枚查见转移癌。患者术后恢复可，入我科后复查CT未见肿瘤复发及转移征象，2016-2-18起给予MFOLFOX6方案化疗5周期，，具体为：奥沙利铂130MG D1+右亚叶酸钙300MG D1+氟尿嘧啶0.625G D1，3.75G 输液泵维持46小时，耐受可。今为行上一周期化疗再次入院。患者自下次出院以来，神志清，精神可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 19,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 37,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 43,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 50,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 73,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 85,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 153,
"label_type": "手术",
"overlap": 0,
"start_pos": 128
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 161
},
{
"end_pos": 175,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 190
},
{
"end_pos": 204,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 233,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 232
},
{
"end_pos": 247,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 240
},
{
"end_pos": 256,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 399,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 396
},
{
"end_pos": 424,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 419
},
{
"end_pos": 430,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 425
},
{
"end_pos": 448,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 444
},
{
"end_pos": 459,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 456
},
{
"end_pos": 490,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 489
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2014-6外院检查发现AFP升高。2014-6-22，六院行CT检查：肝左叶巨大占位，肝癌可能大。2014-7-1来我院就诊，，行MRI检查示：肝左叶巨块型MT，大小约8.4X11.5CM。7/，15查AFP: 6428.0NG/ML；7/18行特殊肝段切除术（V、VI、VIII段）+胆囊切除术。，术后病理：（肝左叶）肝细胞肝癌，III级，伴出血、坏死，脉管内见癌栓。肝切缘未见癌组织累及。周围肝组织汇管区淋巴细胞浸润伴纤维组织增生（G1S2），部分区肝细胞大细胞变。（胆囊）慢性炎。检出胆囊旁淋巴结1枚，慢性炎。免疫组化(2014-N8731)2，号蜡块:AFP(++),HEPA(++),CK7(-),CK19(-),CD34(血窦丰富),KI67(50%阳性),GS(++),HSP70(++),GPC3(-),OPN(-)。术后手术区积液，予以置管引流。7/，25出院前查AFP: 1362.0NG/ML；出院后，随访腹部，CT：肝MT术后改变，术区积液、积气，随访；肝脏囊肿，8/，18随访AFP：113NG/ML。现为进一步介入治疗收入院。患者发病以来，胃纳可、夜寐可、二便正常、体重无明显减轻。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 36,
"label_type": "手术",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 70,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 111,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 132,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 158,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 156
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 231,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 278,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 275
},
{
"end_pos": 305,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 298
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于2016-01-08因“结肠癌”于我院行左半结肠切除+淋巴结清扫术，术后病理示：（01083.16）结合986.16（结肠）中分化腺癌，隆起型，肿瘤切面积8*5.5CM，侵达浆膜，下、上切线均未查见癌，肠周查见淋巴结17枚，其中2枚查见癌（2/17）。（膀胱）结缔组织急慢性炎，其内查见少许异型下皮，考虑为腺癌累及。术后给予抗炎、补液、营养及对症治疗，术后恢复可。现患者无恶心、呕吐，无腹痛、腹胀，大便通畅，为行化疗治疗，今日就诊于我院，门诊以“结肠癌术后化疗”收住入院。患者自发病以来，神志清，精神可，食欲、睡眠可，小便正常，体重变化不明显。高血压病史30余年，未规律服药，现血压正常。患乙型病毒性肝炎20年。尿频、排尿困难1年余，未行治疗。 | |
[
{
"end_pos": 13,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 20,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 37,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 65,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 73,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 141,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 328,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 323
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者1月前因\"间断下腹痛1年，发现结肠占位2天\"于我院行左半结肠切除术，手术顺利，病理回报为（左半结肠）结肠隆起型高中分化腺癌，部分为粘液腺癌，大小10×5×4CM，癌侵及浆膜上纤维脂肪组织，距环周切缘约3MM，未见脉管癌栓，淋巴结未见癌转移（肠周0/13，结肠中血管旁0/2），（近端）及（远端）切缘未见特殊。免疫组化结果显示 CD44(+)，CMET(+)，COX2(+)，EGFR()，HER2(1+)，KI-67(+20%)，MLH1(+50～75%)，MMP7(弱+)，MSH2(+25～50%)，MSH6()，P170()，P27(+25～50%)，P53(+50～75%)，TOPOII(+＜10%)。现患者为求进一步治疗，以“结肠癌术后”收入院。患者自发病以来，精神饮食可，睡眠可，二便正常，体重无明显减轻。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 50,
"label_type": "药物",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 68,
"label_type": "药物",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 72,
"label_type": "药物",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 140,
"label_type": "手术",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 176,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 167
},
{
"end_pos": 223,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 235,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 234
},
{
"end_pos": 248,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 259,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 256
},
{
"end_pos": 267,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 266
},
{
"end_pos": 297,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 296
},
{
"end_pos": 300,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 299
},
{
"end_pos": 322,
"label_type": "药物",
"overlap": 0,
"start_pos": 316
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 332
},
{
"end_pos": 361,
"label_type": "药物",
"overlap": 0,
"start_pos": 355
},
{
"end_pos": 374,
"label_type": "药物",
"overlap": 0,
"start_pos": 371
},
{
"end_pos": 389,
"label_type": "药物",
"overlap": 0,
"start_pos": 386
},
{
"end_pos": 451,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 443
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前5月因诊为降结肠癌伴肝转移，于2016.01.15、2016.02.05在我院予“奥沙利铂200MGIVGTTD1+卡培他滨片(希罗达)1500MGBIDPOD1-14”方案行术前新辅助化疗，未见明显化疗后不良反应，于2016年02月29日于我院行腹腔镜上右半结肠切除术（姑息性），术顺，术后病理回报（201605763）：结肠隆起型黏液腺癌，侵及浆膜上层，侵犯脉管组织，未见肯定神经侵犯。手术标本远、近切端均未见癌浸润。找到肠周淋巴结4/22个，见癌转移。肠周脂肪中找到4枚癌结节。肠粘膜溃疡。另送（右结肠动脉根部）、（肠系膜上静脉根部）镜上为纤维、血管及脂肪组织。术后恢复可，无腹痛、腹胀，无恶心、呕吐等不适，术后予“盐酸伊立替康240MG静滴D1+卡培他滨片1500MGBIDPOD1-14”“盐酸伊立替康240MG静滴D1+安维汀400MG（自备）D1+替吉奥60MGBIDPOD1-14”方案化疗3次，化疗期间予制酸、补液、营养支持等对症处理。为进一步治疗，门诊拟“降结肠癌伴肝转移（PT1N2AM1AIVA期）”收入院，自下次出院以来，精神、睡眠、饮食可，大小便如常，体重未见明显减轻。 | |
[
{
"end_pos": 70,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 160,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 198,
"label_type": "手术",
"overlap": 0,
"start_pos": 188
},
{
"end_pos": 219,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 231,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 236,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 264,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 278,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 273
},
{
"end_pos": 292,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 287
},
{
"end_pos": 308,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 301
},
{
"end_pos": 391,
"label_type": "药物",
"overlap": 0,
"start_pos": 388
},
{
"end_pos": 462,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 460
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2014年上半年无明显诱因出现大便带鲜血，量少，伴大便次数增加至8-10次/天，稀烂，偶有里急后重，2014年11他也前出现间歇性脐周隐痛，大便后可缓解。无恶心、发热等不适。到外院对症处理，便血症状无明显缓解。2015-1-9，外院肠镜检查提示:距肛门17-19CM乙状结肠肿物，肠镜能通过。活检病理提示高分化腺癌。后至我院就诊，完善检查后于2015年1月22日全麻上行腹腔镜上DIXON术，术程顺利，，术后病理结果回报：（乙状结肠大体）镜检为肠中分化腺癌，浸润至肠壁浆膜上层，未见明确脉管内癌栓及神经束侵犯。（中央淋巴结）1枚，未见癌。（中间淋巴结）2枚，未见癌。（肠旁淋巴结）6枚，未见癌。（系膜根部淋巴结）1枚，未见癌。，分期为：PT3N0M0 IIA期。，免疫组化：MLH1（+），MSH2（+），MSH6（+），PMS2（+）。于2015-03-23开始至今行希罗达7程口服化疗顺利,化疗后未出现明显副反应。现患者为进一步诊治入院遵主诊教授意见行本周期化疗。目前患者一般情况可，无发热、咳嗽、身目黄染，无骶部痛等，精神可，纳眠可，小便无异常，手术至今体重约上降15KG。 | |
[
{
"end_pos": 6,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 3
},
{
"end_pos": 32,
"label_type": "手术",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 51,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 106,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 127,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 122
},
{
"end_pos": 146,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 140
},
{
"end_pos": 165,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者因胃MT于2010年1月14日在我科行腹腔镜根治性全胃切除术，术后病理示：(全胃)平坦型低分化腺癌,侵及全层及周围脂肪组织,呈弥漫浸润性生长,侵及神经束,部分脉管可见癌栓,双切缘未见肿瘤累及. 检出小弯淋巴结13枚,其中9枚见癌转移; 检出大弯淋巴结3枚,均可见癌转移; 检出幽门下淋巴结2枚,均未见癌转移; 检出幽门上淋巴结13枚,均见癌转移; 另送14组淋巴结2枚,均可见癌转移; 另送切缘未见癌累及。患者术少量多餐，偶有腹泻，无发热、恶心、呕吐等。已行2次化疗，现为化疗收住入院。 | |
[
{
"end_pos": 24,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 52,
"label_type": "手术",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 68,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 92,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 143,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 152,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 183,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 178
},
{
"end_pos": 210,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 204
},
{
"end_pos": 237,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 347,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 350,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 349
},
{
"end_pos": 380,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 376
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者近1月前（2016-02-23）前因“胃癌”于我院行胃癌姑息性切除术（远端胃大部切除+毕I式吻合），，术中探查见：肿瘤位于胃窦小弯侧，大小约5*4*3CM,侵透浆膜并侵及胰腺，胃周可见多组肿大淋巴结，其中7、8、9组淋巴结融合成团，并与胰腺浸润。，术后常规病理示：（胃）低分化腺癌，局灶伴印戒细胞癌分化，弥漫浸润型，肿瘤切面积5.5*0.8CM，侵及胃壁深肌层。双端切缘、吻合器切缘及网膜组织未查见癌。大弯侧淋巴结11枚，其中3枚（3/11）查见转移；第7、8组淋巴结9枚，其中1枚（1/9）查见转移；小弯侧淋巴结8枚，均未查见转移（0/8）。，免疫组化：CK（+）、HER-2（2+）、SYN（-）、E-CAD（+）。术后给予消炎、营养支持治疗，病情好转后出院。现患者无恶心、呕吐，无腹痛、腹胀，半流质饮食，二便正常。现为求进一步治疗，门诊以“胃癌术后”收入院。自下次出院来，神志清，精神可，饮食可，体重较前无明显改变。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 49,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 58,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 63,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 88,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 99,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 145,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 163,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 228,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 223
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 315,
"label_type": "药物",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 466,
"label_type": "药物",
"overlap": 0,
"start_pos": 462
},
{
"end_pos": 470,
"label_type": "药物",
"overlap": 0,
"start_pos": 467
},
{
"end_pos": 489,
"label_type": "药物",
"overlap": 0,
"start_pos": 484
},
{
"end_pos": 493,
"label_type": "药物",
"overlap": 0,
"start_pos": 490
},
{
"end_pos": 520,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 519
},
{
"end_pos": 523,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 522
},
{
"end_pos": 564,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 559
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月余于我院诊为直肠癌，于2016.01.12在全麻上行腹腔镜上直肠癌根治术DIXON，，术中见：上腹部粘连，腹腔内无明显出血，无明显腹水，盆腔、腹壁、大网膜、肝脏未见明显转移结节，腹腔位于直肠下段，大小约3*2.5CM，可疑侵及浆膜层。术后病理（201601067），：(直肠)，：肠隆起型绒毛状-管状腺癌II级，局灶性浸润深肌层（>1/2肌层），并见淋巴管内癌栓。手术标本双切端及另送（下切端）、(上切端)均未见癌浸润。找到肠周淋巴结9个（经本组下级医师复核淋巴结），另送(肠系膜上动脉根部）淋巴结1个，均未见癌转移。，免疫组化染色结果：KI67（60%阳性），P53（+++），P170（+++），5-FU（++），MLH1（+++），MSH2（+++），PMS2（+++），MSH-6（+++）。DNA错配修复的MMR蛋白（PMS2、MSH6、MLH1和MSH2）免疫组化染色提示本例肿瘤微卫星稳定（MSS）。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲出院。于2016.01.30行“奥沙利铂(乐沙定)150MGIVGTTD1+卡培他滨片(希罗达)1000MGPOBIDD1-14”方案化疗，辅以保胃、保肝、止吐等治疗，未见明显化疗副反应。今为行第2次化疗再次就诊我院，门诊拟“直肠癌术后化疗”收住入院。自下次出院以来，。 | |
[
{
"end_pos": 74,
"label_type": "手术",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 121,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 171,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 181,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 176
},
{
"end_pos": 202,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 189
},
{
"end_pos": 223,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 243,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 228
},
{
"end_pos": 256,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 271,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 284,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 415,
"label_type": "药物",
"overlap": 0,
"start_pos": 413
},
{
"end_pos": 427,
"label_type": "药物",
"overlap": 0,
"start_pos": 424
},
{
"end_pos": 449,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 448
},
{
"end_pos": 452,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 451
},
{
"end_pos": 493,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 488
},
{
"end_pos": 506,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 505
},
{
"end_pos": 514,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 512
},
{
"end_pos": 518,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 517
},
{
"end_pos": 521,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 520
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于4月前因反复进食阻塞3个月就诊于我院，完善术前准备后，于20160106行胸腹腔镜联合全胸段食管切除+食管-胃底右颈部吻合+右甲状腺结节切除术。手术顺利，术后恢复良好后出院，，术后病理示：（食管及胃底）食管多中心性蕈伞型鳞状细胞癌II级，侵及外膜层，侵犯神经及脉管组织，手术标本下、上切端及另送(最下切端)均未见癌浸润。找到食管周淋巴结0/2个，胃周淋巴结0/5个，及另送(右喉返喉返神经旁)淋巴结0/16个，（左喉返喉返神经神经旁）淋巴结0/5个，(颈部右喉返喉返神经旁)淋巴结1/1个，(隆突上)淋巴结0/2个，(上段食管旁)淋巴结0/5个，（贲门旁）淋巴结0/4个见癌转移。，免疫组化：肿瘤细胞示KI67（60%阳性），CK(H)（+），P63（+），P53（个别细胞阳性），P170（++），GSTπ（-），EGFR（++）。排除化疗禁忌症后于2016-02-03，2016-02-28，2016-03-22以“顺铂40MGD1-3，紫杉醇210MGD2”方案行3周期次化疗，辅以保肝，护胃，提高免疫力等处理，未见明显化疗副反应。现为求第4次化疗，就诊我科，拟“食管癌术后”入我科。下次出院至今无胸闷、憋气；无胸背痛；无腹痛、腹胀；无呕血、黑便；偶有返酸。饮食睡眠较好。大小便正常。体重无明显变化。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 43,
"label_type": "手术",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 51,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 62,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 93,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 100,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 98
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 135,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 205,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 253,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 264,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 258
},
{
"end_pos": 275,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 269
},
{
"end_pos": 286,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 280
},
{
"end_pos": 303,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 317,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 315
},
{
"end_pos": 326,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 324
},
{
"end_pos": 335,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 353,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 427,
"label_type": "药物",
"overlap": 0,
"start_pos": 423
},
{
"end_pos": 487,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 483
},
{
"end_pos": 509,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 508
},
{
"end_pos": 512,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 511
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月于我院诊为胃癌，于2013-11-29在全麻上行根治性远端胃大部切除术，，术中见：腹腔内无明显腹水，盆腔、腹壁、大网膜无转移结节，肝脏质地大小正常，未及明显转移结节。胃腔扩张明显，胃壁水肿增厚，肿瘤位于幽门管大弯侧偏前壁，活动度可，侵出浆膜层，未侵犯胰腺，周围可及肿大淋巴结。术后病理示（201337693）(远端胃)，：胃窦溃疡型管状腺癌II-III级，少部分为低粘附性癌（主要为印戒细胞癌），脉管内见癌栓，侵出浆膜层，手术标本下切端、上切端及另送(下切端)均未见癌浸润。找到大弯侧淋巴结0/1个，小弯侧淋巴结4/6个，幽门下淋巴结4/6个，幽门上淋巴结4/7个另送(胃右动脉根部)淋巴结1/9个，见癌转移。找到小弯侧癌结节1个，幽门下癌结节1个，幽门上癌结节1个，另送(第14V组淋巴结)镜上为脉管、脂肪、纤维结缔组织。，免疫组化结果：KI67（75%阳性），P53（+++），P170（-），GSTπ（+），EGFR（-），5-FU（++），HER-2（-）。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。此次为化疗就诊我院，门诊拟胃癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 63,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 86,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 120,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 123
},
{
"end_pos": 130,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 127
},
{
"end_pos": 160,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 165
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 209
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于2014年05月因“子宫内膜癌”于******健院行“腹腔镜上广泛切除术+两附件切除术+盆腔LN及腹主动脉旁淋巴结清扫术”术后病理为“子宫内膜样腺鳞癌II级伴鳞状生化”。2014年5月至7月行TC方案化疗3程。2015年11月复查CT提示“盆腔以及两侧髂血管旁多发肿大淋巴结，考虑M”。2015年12月PET/CT示“两髂及两闭孔多个淋巴结代谢活跃，考虑M”。遂至我院就诊，当时因患者拒绝化疗未及时治疗。现患者诉阴道口瘙痒严重，里急后重感，于2016-03-07给予TC（进口）方案化疗1程。今再次来我院就诊。患者发病以来,精神一般,饮食睡眠不佳,大小便不正常：里急后重感，体重有减轻。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 95,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 137
},
{
"end_pos": 174,
"label_type": "药物",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 192,
"label_type": "药物",
"overlap": 0,
"start_pos": 188
},
{
"end_pos": 211,
"label_type": "药物",
"overlap": 0,
"start_pos": 207
},
{
"end_pos": 219,
"label_type": "药物",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 297,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 289
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者约于7年前因“结肠癌”于2009-09-08日在全麻上行左半结肠切除术。手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好。，术后病理：（7282.2009）结肠腺癌（中低度分化），浸润溃疡型，面积4*3CM，侵达浆膜脂肪组织。累及阑尾浆膜面。双端切线未查见癌。呈一站（1/22）个淋巴结癌转移。术后给予患者化疗6周期，，方案为：奥沙利铂200MG D1（1-3期）奥沙利铂150MG D1（4-6期），亚叶酸钙0.3G+替加氟1.0G D2-D6。现患者腹胀，食欲差，就诊于我院门诊。 患者院外就诊期间，神志清，精神可，大、小便正常，体重未见明显变化。门诊以“左半结肠切除术后7年余”收入我院。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 23,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 51,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 68,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 93,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 107,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 118,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 125
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 158,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 339,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 338
},
{
"end_pos": 342,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 345,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 344
},
{
"end_pos": 386,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 382
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于4月前因“下腹部闷痛不适”腹部CT提示肝占位，进一步于我院行“腹腔镜上右肝肿物切除术+胆囊切除术”。，术后病理报告示：1.（右肝脏肿物），：肝脏原发性中分化肝细胞-胆管细胞混合型癌，伴坏死，侵及肝被膜及周边肝组织。癌周肝脏组织，肝细胞水肿变性，汇管区小胆管增生，伴中量慢性炎症细胞浸润。2（胆囊），：慢性胆囊炎。，免疫组化：CK7(-),CK20（+++），VILLIN(+++)，CDX-2(-),CK19(+++),CA19-9(-),GLYPICAN-3（+），CEA（-），KI67(70%),TTF-1(-),NSE(-),SY(-),PAS(灶性区域少量阳性)，AB染色（-）。术后患者无不适。无畏寒、寒战、发热，无恶心、呕吐、纳差，无皮肤黄、眼黄、尿黄。无腹痛、腹胀、腹泻，无返酸，嗳气。定期我院门诊随访，评估病情稳定。今为复查来我院，门诊拟“肝癌术后”收入院。自发病以来，食欲正常，睡眠、精神可，体重无明显上降，大、小便正常。 | |
[
{
"end_pos": 35,
"label_type": "手术",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 59,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 93,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 163
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者于2011.8.3在全麻上行剖腹探查+肠减压+根治性左半结肠切除术，术后恢复可，病理类型为结肠溃疡型中分化管状腺癌，浸及肠壁全层，脉管内见癌栓。双切端及阑尾均未见癌累及。肠壁下淋巴结未见癌转移（0/12），另送（系膜）组织未见癌转移，分期(T4N0M0) 。术后已行6次FOLFOX方案全身化疗，化疗期间患者无恶心、呕吐、腹泻等不适，化疗过程顺利，本次为术后复查入院。\U0004 患者本次发病以来，食欲正常， 神志清醒，精神尚可，睡眠尚可，大便正常，小便正常，体重无明显变化。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 68,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 112,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 156,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 161
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 172
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 205
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 240,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 231
},
{
"end_pos": 254,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 268,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 259
},
{
"end_pos": 284,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 278
},
{
"end_pos": 307,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 305
},
{
"end_pos": 382,
"label_type": "药物",
"overlap": 0,
"start_pos": 378
},
{
"end_pos": 398,
"label_type": "药物",
"overlap": 0,
"start_pos": 395
},
{
"end_pos": 424,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 423
},
{
"end_pos": 483,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 461
},
{
"end_pos": 503,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 502
},
{
"end_pos": 506,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 505
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，入院前3个月余于我院诊为胃癌，于2015年04月06日在全麻上行“腔镜上根治性全胃切除术+食管空肠ROUX-Y吻合术（D2）+脾切除术”。术后病理（201512223），：(全胃)，：食管胃交界溃疡型管状腺癌II-III级，侵及浆膜层，累及神经。手术标本下、上切端及另送(下切端)均未见癌浸润。找到贲门周淋巴结1/3个，小弯淋巴结1/11个，大弯淋巴结1/1个，幽门上0/5个，另送(第7组）淋巴结0/1个，(第8组）淋巴结0/1个，(第9组）淋巴结1/4个，(第10组）淋巴结1/3个，(第11组）淋巴结1/2个，(第15组）淋巴结0/1个，见癌转移。幽门下淋巴结及另送(第12组淋巴结)未查见淋巴结。另送脾脏组织，未见癌浸润。术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。于2015.05.04、2015.06.23、2015.06.13行“奥沙利铂200MGIVGTTD1+替吉奥60MGPOBIDD1-14”方案化疗3次，辅予保胃、制酸、止吐、补液等，无明显药物毒性反应。今为术后第4次辅助化疗,门诊以“胃贲门管状腺癌（PT4AN2M0IIIB期）术后”收入院。自出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 45,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 58,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 87,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 101,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 147,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 250,
"label_type": "药物",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 272,
"label_type": "药物",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 296,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 295
},
{
"end_pos": 299,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 333,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 328
},
{
"end_pos": 355,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 354
},
{
"end_pos": 358,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 357
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2月余前于我院确诊为“直肠癌”，2015.07.11日行腹腔镜上直肠部分切除术,术后予以制酸,抗炎,护胃等对症处理,术后病理示(201525467)，:，：(直肠)，：肠隆起型管状腺癌II级，伴坏死，侵及外膜层，手术标本双切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结13个均未见癌转移。(MM20151216)，:该病例未检测到KRAS基因12、13号密码子热点突变。该病例未检测到BRAF基因V600E突变，术后于2015.07.29、2015.08.25予以“卡培他滨1500MGPOBIDD1-D14+奥沙利铂200MGD1IVGTT”方案化疗,期间辅以保胃,保肝止呕吐等对症处理。此次为行第3周期化疗再次就诊我院，门诊拟直肠癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 9,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 7
},
{
"end_pos": 49,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 62,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 56
},
{
"end_pos": 66,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 107,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 111,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 272,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 271
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，其于1月前因结肠占位性病变于2013.06.13下午在全麻上行遂行结肠癌根治术+放射性粒子置入术，术中冰冻提示乙状结肠腺癌，侵及肠壁深肌层，双切缘阴性。手术顺利，，术后病检提示：乙状结肠溃疡型中分化管状乳头状腺癌，浸及肠壁全层，脉管、神经未见癌侵犯，双切端未见癌累及，淋巴结见癌转移（1/5），，肿瘤分期：T3NXM1 。术后予以预防感染、抗肿瘤等对症支持治疗，恢复良好，并于2013.06.24治愈出院。出院后食欲较好，体重增加约6KG，未诉特殊不适，今患者为行第1次全身静脉化疗入院。\U0004 患者发病以来，神志 清晰，精神可，胃纳可，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 12,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 47,
"label_type": "手术",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 65,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 112,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 177,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 161
},
{
"end_pos": 262,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 284,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 271
},
{
"end_pos": 359,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 358
},
{
"end_pos": 362,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 361
},
{
"end_pos": 448,
"label_type": "药物",
"overlap": 0,
"start_pos": 444
},
{
"end_pos": 465,
"label_type": "药物",
"overlap": 0,
"start_pos": 461
},
{
"end_pos": 508,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 503
},
{
"end_pos": 533,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 532
},
{
"end_pos": 536,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 535
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于5月余前因“直肠癌”就诊我院,于2016.06.29行“腔镜上直肠根治术（DIXON手术）”，探查腹腔内无明显出血，无明显腹水，无明显粘连，无明显腹腔肿瘤种植转移，肿瘤位于腹膜返折下7CM，侵出前壁浆膜层，未形成肠梗阻，近端无扩张，周围少许肿大淋巴结。术顺，术后予预防感染、制酸、补液、营养支持等治疗，，术后病理示：（直肠）大肠溃疡型管状腺癌II级，侵出外膜层，可见脉管内癌栓，未见明确神经侵犯。，病理：手术标本双切端及另送（下切端）、（上切端）均未见癌浸润，另送（上切端）灶性腺下皮呈低级别下皮内瘤变。找到肠周淋巴结1/24个，及另送（肠系膜上动脉根部）淋巴结0/1个，见癌转移。，免疫组化：KI67（60%+），P53（+++），CK7（-），CK20（+++），CEA（++）。术后恢复可，无恶心、呕吐、腹痛、腹胀、发热、畏寒等不适。术后于2016.07.26、2016.08.17、2016.09.12、2016.10.08、2016.10.30、2016.11.21予以“奥沙利铂150MGIVGTTD1+卡培他滨1500MGBIDD1-D14”方案化疗，为行上一周期化疗，就诊我院,门诊拟直肠癌术后化疗收治入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 7,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 4
},
{
"end_pos": 26,
"label_type": "手术",
"overlap": 0,
"start_pos": 20
},
{
"end_pos": 35,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 41
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因直肠癌于2014年12月05日行直肠前切除术，，术后病理：直肠（切除），：溃疡型中分化腺癌，肿物最大径6CM；侵及周围脂肪组织及浆膜上层；可见脉管癌栓； 淋巴结可见癌转移（19/24）； - 环周切缘、（近端）及（远端）均未见癌；另送肠管未见癌； ，肿瘤病理分期：PT3N2B。现为行术后辅助化疗入院，患者自发病以来精神睡眠食欲尚好，小便如常，大便如下述，体重无明显改变。 | |
[
{
"end_pos": 24,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 59,
"label_type": "手术",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 87,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 92,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 114
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 145,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 140
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者1月余前于我院诊断为“乙状结肠肿物，恶性待排”完善术前检查，排除手术禁忌症后于2013-01-31行乙状结肠切除术，术后恢复可，有排气排便，术后病理示：乙状结肠中分化腺癌，浸润至肠壁粘膜上层，未见神经束侵犯，未见脉管内癌栓，中间淋巴结转移一枚（1/7），中央淋巴结（0/5），肠旁淋巴结（0/2），患者术后于2013年2月26日开始行XELOX方案化疗5程，过程顺利，现为进一步治疗入住本科。患者自下次出院以来，食欲、睡眠及精神良好，小便正常，体力无上降，体重无明显上降。 | |
[
{
"end_pos": 43,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 81,
"label_type": "手术",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 93,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 109,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 127,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 125
},
{
"end_pos": 157,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 165,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 214,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 246,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 251,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 249
},
{
"end_pos": 282,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 291,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 285
},
{
"end_pos": 358,
"label_type": "药物",
"overlap": 0,
"start_pos": 354
},
{
"end_pos": 374,
"label_type": "药物",
"overlap": 0,
"start_pos": 371
},
{
"end_pos": 422,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 417
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4个月(2015-09-14)，于我院查肠镜：升结肠肠乳头状管状腺癌II级，遂于3个月前(2015年09月21日)全麻上行腹腔镜上左半结肠根治性切除术，，术中探查见：探查腹腔内无明显出血，无明显腹水，升结肠可见肿瘤，近端几达回盲部，远端近肝曲，明显侵出浆膜层，与周围组织稍明显粘连，未形成梗阻，近端肠管无扩张，周围及肠系膜根部可见数个肿大淋巴结；术后病理(N201503896)，：左半结肠回盲部隆起型管状腺癌II级，伴神经内分泌分化及坏死，侵及浆膜层，脉管内见癌栓，手术标本结肠切端、回肠切端及另送（下切端）、（上切端）均未见癌浸润。找到回肠周淋巴结2个，结肠周淋巴结29个均未见癌转移。术顺，术后分别于2015-10-22、2015-11-13、2015-12-05、2015-12-27行“奥沙利铂D1200MGIVGTT+希罗达D2-141500MGPOBID”方案化疗4次，化疗过程顺利，今为进一步化疗，门诊拟“结肠癌术后”收住入院。自下次出院以来，精神、食欲、睡眠尚可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 20,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 67,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 87,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 97,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 105,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 107,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 110,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 121,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 159,
"label_type": "手术",
"overlap": 0,
"start_pos": 146
},
{
"end_pos": 171,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 190,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 184
},
{
"end_pos": 297,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 291
},
{
"end_pos": 330,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 325
},
{
"end_pos": 346,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 342
},
{
"end_pos": 365,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 379,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 378
},
{
"end_pos": 394,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 391
},
{
"end_pos": 398,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 395
},
{
"end_pos": 401,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 399
},
{
"end_pos": 424,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 421
},
{
"end_pos": 453,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 447
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2016年4月初无明显诱因出现腹部绞痛，伴恶心、呕吐，无呕血、黄疸等不适，在院外考虑“肠套叠”，遂转至**一院就诊，入院后行CT检查提示全身多发性淋巴结肿大，考虑淋巴瘤；左上腹回-回肠套叠，考虑小肠淋巴瘤；脾大，脾内多发结节，考虑淋巴瘤。完善相关检查后于2016-04-08在**一院行腹腔镜探查、左半结肠切除术，，术后病理回报：送检肠管见一息肉样肿物，病变符合套细胞淋巴瘤，，免疫组化：CYCLIND1、CD5、CD20、CD79A、BCL-2、SOX11均为（+），CD23、CD3、CD10、BCL-6均为（-），KI67(30%+)。术后恢复可。2016-04-20查PET/CT，提示：全身多发淋巴结肿大，最大者约1.4*1.0CM(右颈部V区)、4.6*3.2CM(左髂血管旁)、5.9*2.6CM(左侧腹股沟区，SUVMAX 4.2)；脾大，代谢不均匀增高，符合淋巴瘤；中轴骨、骨盆骨髓弥漫性代谢轻度增高，考虑反应性改变与淋巴瘤累及鉴别。现为进一步治疗，来我院就诊，门诊拟“套细胞淋巴瘤”收入我科。起病以来，患者未诉发热、偶有盗汗，术后近一月体重上降5KG。精神稍差，食欲、睡眠可，大小便正常。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 55,
"label_type": "手术",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 66,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 84,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 127
},
{
"end_pos": 147,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 181,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 178
},
{
"end_pos": 187,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 190
},
{
"end_pos": 201,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 206,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 202
},
{
"end_pos": 210,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 207
},
{
"end_pos": 225,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 228,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 256,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 268,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 283,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 273
},
{
"end_pos": 311,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 317,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 312
},
{
"end_pos": 328,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 324
},
{
"end_pos": 335,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 331
},
{
"end_pos": 340,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 339
},
{
"end_pos": 364,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 356
},
{
"end_pos": 372,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 370
},
{
"end_pos": 381,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 377
},
{
"end_pos": 387,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 382
},
{
"end_pos": 494,
"label_type": "药物",
"overlap": 0,
"start_pos": 492
},
{
"end_pos": 503,
"label_type": "药物",
"overlap": 0,
"start_pos": 500
},
{
"end_pos": 540,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 535
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2015.11.27因“卵巢癌”于我院全麻上行经腹子宫+两侧附件切除+大网膜切除+部分肠壁转移病灶切除术。，术中探查见：盆腹腔可见淡黄色腹水，量约500ML，子宫前位，萎缩，前壁可见菜花样结节，右侧卵巢约3*2CM大小，表面不规则菜花状突起，质脆，左侧卵巢约2*2CM大小，形态似右侧卵巢，大网膜挛缩呈厚饼状，质硬，与肠管形成致密粘连，结肠、升结肠、横结肠、直肠前前壁肿物与肠管致密粘连，直肠前壁、结肠肝区及肝上极均可见不规则菜花样突起，腹盆壁、小肠表面可见大量结节样突起，质脆，易脱落。，术中切除右侧附件送快速病理回示：（右附件）图像符合高级别浆液性乳头状癌。，术后常规病理示：（两附件区）卵巢高级别浆液性乳头状癌，两侧输卵管查见癌，肿瘤自子宫浆膜面侵达宫壁肌层，送检（肠壁转移灶）和大网膜组织均查见癌；右、左宫宫旁组织未查见癌。（子宫）萎缩状态子宫内膜。慢性宫颈炎。，免疫组化：ER（80%+），PR（-），WT-1（+），P53（+）。术后恢复可，根据术后病理，于2015.12.06、2015.12.30、2016.01.21、2016.2.14、2016.3.10给予顺铂120MG+多帕菲120MG方案化疗5疗程，现患者欲行第6次化疗来院就诊，门诊以“卵巢癌术后化疗”收入院，患者者饮食睡眠正常，大小便无异常，体重无明显增减。 |